Methods of Treating Dry Eye Disease Using TNFα Antagonists
By identifying patients with the rs1800693 response allele, personalized TNFα antagonist therapy effectively treats DED, improving symptoms and reducing treatment frequency.
Patent Information
- Application Number
- JP2018566485
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2016-06-20
- Filing Date
- 2017-06-19
- Publication Date
- 2024-11-14
- Estimated Expiration
- 2037-06-19
AI Technical Summary
Current treatments for dry eye disease (DED) do not fully address the root cause and require frequent application, leading to inconvenience and high costs, while existing anti-TNFα therapies for DED have not been evaluated despite evidence of TNFα involvement.
Identify patients likely to respond to TNFα antagonists by detecting the rs1800693 response allele, allowing personalized therapy with TNFα antagonists like LME636 to treat DED effectively.
Personalized therapy with TNFα antagonists significantly improves symptoms in DED patients carrying the rs1800693 response allele, reducing the frequency of treatment applications and minimizing side effects.
Smart Images

Figure 0007583515000027 
Figure 0007583515000028 
Figure 0007583515000029
Abstract
Description
[Technical field]
[0001] The present disclosure relates to predictive methods, personalized therapy, kits, transferable forms of information and methods of treating patients with dry eye disease. [Background technology]
[0002] Dry eye disease (DED) is a common multifactorial disorder of the tears and ocular surface characterized by ocular surface inflammation and increased tear film osmolality resulting in symptoms of discomfort, visual impairment, and tear film instability (Lienert JP, Tarko L, Uchino M, Christen WG, Schaumberg DA. (2016). Long-term Natural History of Dry Eye Disease from the Patient's Perspective. Ophthalmology. 123(2):425-33). The only available pharmacological treatment is topical cyclosporine, an anti-inflammatory agent approved to increase tear production. Steroids are also used to treat DED, but long-term use is contraindicated due to side effects. For more severe forms of DED, serum eye drops and scleral contact lenses are recommended. However, none of these treatments adequately address the underlying causes of DED (Marshall LL, Roach JM. (2016). Treatment of Dry Eye Disease. Consult Pharm. 2016;31(2):96-106).
[0003] Dry eye, also called keratoconjunctivitis sicca, is a common ophthalmic disorder that affects millions of people every year. The condition is especially prevalent in postmenopausal women due to hormonal changes after loss of fertility. Dry eye can vary in severity in affected individuals. In mild cases, patients may experience burning, dryness, and persistent irritation, often caused by small foreign bodies lodged between the eyelid and the ocular surface. In severe cases, vision may be substantially impaired. Other diseases, such as Sjogren's syndrome and cicatricial pemphigoid, can also lead to dry eye conditions. Transient dry eye symptoms associated with refractive surgery have been reported, sometimes lasting 6 weeks to 6 months or more after surgery.
[0004] Although dry eye appears to be caused by a number of unrelated pathogenic causes, the complication manifestations all share a common effect: breakdown of the anterior tear film with resulting exposure of the ocular surface, water loss, and cytokine production, resulting in many of the symptoms outlined above (Lemp, Report of the National Eye Institute / Industry Workshop on Clinical Trials in Dry Eyes, The CLAO Journal, volume 21, number 4, pages 221-231 (1995)).
[0005] Doctors have taken several approaches to treating dry eye. One common approach is to replenish and stabilize the eye's tear film using so-called artificial tear drops administered throughout the day. Other approaches include the use of intraocular inserts (e.g., punctal plugs) that promote tear retention or stimulating endogenous tear production.
[0006] Examples of tear substitute techniques include buffered isotonic saline, aqueous solutions containing water-soluble polymers that make the solution highly viscous and therefore difficult to drain from the eye.Stabilization of the tear film by providing one or more components of the tear film, such as phospholipids and oils, has also been attempted.Phospholipid compositions have been shown to be useful in the treatment of dry eye; see, for example, McCulley and Shine, Tear film structure and dry eye, Contactologia, volume 20(4), pages 145-49 (1998); and Shine and McCulley, Keratoconjunctivitis sicca associated with meibomian secretion polar lipid abnormality, Archives of Ophthalmology, volume 116(7), pages 849-52 (1998).
[0007] Another approach involves providing a lubricating substance in place of artificial tears. For example, U.S. Patent No. 4,818,537 (Guo) discloses a lubricating liposome-based composition, and U.S. Patent No. 5,800,807 (Hu et al.) discloses a composition containing glycerin and propylene glycol for the treatment of dry eye.
[0008] Despite the limited success of these approaches, treating dry eye remains problematic because, although tear substitutes are temporarily effective, they generally require repeated application while the patient is awake. It is not uncommon for patients to have to apply artificial tear solutions 10-20 times a day, which can be cumbersome and time-consuming, as well as very costly.
[0009] Besides the above-mentioned attempts that are mainly aimed at symptomatic relief of the symptoms associated with dry eye, methods and compositions are also sought for the treatment of the physiological conditions that cause such symptoms.For example, US Patent No. 5,041,434 (Lubkin) discloses the use of sex steroids such as conjugated estrogens to treat dry eye conditions in postmenopausal women; US Patent No. 5,290,572 (MacKeen) discloses the use of micronized calcium ion compositions to stimulate anterior tear film production.
[0010] Such attempts to treat the underlying causes of dry eye have focused on treating the associated inflammation of ocular tissues and meibomian gland dysfunction. The use of various drugs for such treatment of dry eye patients has been reported, including steroids (e.g., U.S. Pat. No. 5,958,912; Marsh et al., Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjoegren's syndrome, Ophthalmology, 106(4):811-816 (1999); and Pflugfelder et al., U.S. Pat. No. 6,153,607), cytokine release inhibitors (Yanni, JM; et. al. WO 00 / 03705 A1), cyclosporine A (Tauber, J. Adv. Exp. Med. Biol. 1998, 438 (Lacrimal Gland, Tear Film, and Dry Eye Syndromes 2), 969), and mucosecretatogues, such as 15-HETE (Yanni No. 5,696,166).
[0011] Many studies have reported an increase in inflammatory cytokines, including tumor necrosis factor alpha (TNF-α), in affected tissues (Massingale ML, Li X, Vallabhajosyula M, Chen D, Wei Y, et al. (2009). Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea. 28(9): 1023-7; Chen Y, Zhang X, Yang L, Li M, Li B, et al. (2014). Decreased PPAR-γ expression in the conjunctiva and increased expression of TNF-α and IL-1β in the conjunctiva and tear fluid of dry eye mice. Mol Med Rep. 9(5): 2015-23). A correlation has also been observed between TNFα levels in tear or conjunctival tissue and clinical severity of DED (Lee SY, Han SJ, Nam SM, Yoon SC, Ahn JM, et al. (2013). Analysis of tear cytokines and clinical correlations in Sjoegren syndrome dry eye patients and non-Sjoegren syndrome dry eye patients. Am J Ophthalmol. 156(2):247-253). TNF-α is a pleiotropic cytokine that is involved in regulating cell trafficking, activation, and host defense against various pathogens upon binding to its receptor. Anti-TNF agents have demonstrated clinical efficacy in the treatment of human autoimmune diseases, including rheumatoid arthritis and Crohn's disease.However, topical anti-TNF therapy for DED has not been evaluated despite evidence of TNF-α involvement in DED (Ji YW, Byun YJ, Choi W, Jeong E, Kim JS, et al. (2013). Neutralization of ocular surface TNF-α reduces ocular surface and lacrimal gland inflammation induced by in vivo dry eye. Invest Ophthalmol Vis Sci. 54(12):7557-66).
[0012] A recent study by Hallak et al. showed that Val66Met in the brain-derived neurotrophic factor (BDNF) gene and two SNPs in the vitamin D receptor (VDR) gene, Fokl and Apal, may be associated with DED (Hallak et al., Investigative Ophthalmology & Visual Science September 2015, Vol. 56, 5990-5996). However, there are no known SNPs that can identify DED patients who are most likely to benefit from TNFα antagonism. Summary of the Invention [Means for solving the problem]
[0013] Provided herein are novel predictive methods and personalized therapies for patients with dry eye disease (DED) that maximize the benefits and minimize the risks of TNFα antagonism in these populations by identifying patients likely to respond well prior to treatment with TNFα antagonists. This discovery is based, in part, on the determination that DED patients who carry a DED response marker selected from the rs1800693 response allele exhibit improved response to LME636 compared to DED patients who do not carry this allele.
[0014] Thus, the inventors contemplate that testing subjects for the presence of the rs1800693 response allele may be useful in various pharmaceutical products and methods, including identifying DED patients who are likely to respond to TNFα antagonism, and in aiding physicians in deciding whether to prescribe a TNFα antagonist (e.g., LME636) to those patients, or an alternative therapeutic regimen.
[0015] Accordingly, one object of the present disclosure is to provide a method of treating a patient with DED by administering to the patient a therapeutically effective amount of a TNFα antagonist, e.g., a TNFα antibody, such as LME636, based on certain aspects of the patient's biochemical profile. Another object of the present disclosure is to provide a method of identifying a patient with DED who is likely to respond to treatment with a TNFα antagonist, e.g., a TNFα antibody, such as LME636, based on certain aspects of the patient's biochemical profile. Another object of the present disclosure is a method of determining the likelihood that a patient with DED will respond to treatment with a TNFα antagonist, e.g., a TNFα antibody, such as LME636, based on certain aspects of the patient's biochemical profile.
[0016] Disclosed herein are various methods for selectively treating patients with DED. In some embodiments, these methods include assaying a biological sample from the patient for a DED response marker of the present disclosure; and then selectively administering to the patient a therapeutically effective amount of a TNFα antagonist, such as a TNFα antibody, e.g., LME636, if the patient has the response marker.
[0017] Also disclosed herein are various methods of predicting the likelihood that a patient with DED will respond to treatment with a TNFα antagonist, e.g., a TNFα antibody such as LME636. In some embodiments, these methods comprise detecting a DED response marker of the present disclosure in a biological sample from the patient, where the presence of the response marker indicates an increased likelihood that the patient will respond to treatment with a TNFα antagonist.
[0018] In preferred embodiments, the TNFα antagonist is a TNFα binding molecule, preferably an antibody or antigen-binding portion thereof, most preferably LME636. In some embodiments, the DED response marker is at least one DED response marker as shown in Table 1.
[0019] Additional methods, uses, and kits are provided in the following description and appended claims. Further features, advantages, and aspects of the present disclosure will become apparent to those skilled in the art from the following description and appended claims. [Brief description of the drawings]
[0020] [Figure 1] Symptom change from baseline to day 43 for 12 patients with the rs1800693 CC genotype (4 patients treated with LME636 and 8 patients treated with vehicle). [Diagram 2] FIG. 13 is a waterfall plot showing the change from baseline in global ocular discomfort score at day 26 for all patients treated with LME636 or vehicle, allowing visualization of symptomatic changes by treatment and rs1800693 genotype. [Diagram 3] FIG. 13 is a waterfall plot showing the change from baseline in global ocular discomfort score at day 27 for all patients treated with LME636 or vehicle, allowing visualization of symptomatic changes by treatment and rs1800693 genotype. [Figure 4] FIG. 13 is a waterfall plot showing the change from baseline in global ocular discomfort score at day 28 for all patients treated with LME636 or vehicle, allowing visualization of symptomatic changes by treatment and rs1800693 genotype. [Diagram 5] FIG. 13 is a waterfall plot showing the change from baseline in global ocular discomfort score at day 29 for all patients treated with LME636 or vehicle, allowing visualization of symptomatic changes by treatment and rs1800693 genotype. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0021] The term "comprising" encompasses "including" as well as "consisting", e.g. a composition "comprising" X may consist only of X, or it may include something additional, e.g. X+Y.
[0022] The term "about" with respect to a numerical value x means ±10%, unless the context indicates otherwise.
[0023] As used herein, the terms "subject" and "patient" include any human or non-human animal. The term "non-human animal" includes all vertebrates, e.g., mammals and non-mammals, such as non-human primates, sheep, dogs, cats, horses, cows, chickens, amphibians, reptiles, etc.
[0024] The term "assaying" is used to refer to the act of identifying, screening, probing, testing, measuring, or determining, which may be performed by any conventional means. For example, a sample may be assayed for the presence of a particular gene or protein marker by using ELISA assays, Northern blots, imaging, serotyping, cell typing, gene sequencing, phenotyping, haplotyping, immunohistochemistry, Western blots, mass spectrometry, and the like. The term "detecting" (and the like) refers to the act of extracting particular information from a given source, which may be direct or indirect. In some embodiments of the predictive methods disclosed herein, the presence of a given thing (e.g., an allele, a protein level, and the like) is detected in a biological sample indirectly, for example, by querying a database. The terms "assaying" and "determining" contemplate the transformation of a substance, for example, the transformation of a biological sample, such as a blood sample or other tissue sample, from one state to another by subjecting the sample to a physical test.
[0025] The term "obtain" means to procure, e.g., to acquire as a possession in some manner, e.g., by physical intervention (e.g., a biopsy, a blood draw) or non-physical intervention (e.g., transmitting information via a server).
[0026] The phrase "assaying a biological sample..." and the like is used to mean that the sample may be tested (either directly or indirectly) for either the presence of a given DED response marker. In situations where the presence of a substance means one probability and the absence of a substance means another, it will be understood that either the presence or absence of such substance may be used to guide treatment decisions. For example, determining whether a patient has a DED response marker may be by determining that a particular response allele is indeed present in the patient, or by determining that a particular response allele is not present in the patient. In either such case, it has been determined whether the patient has the presence of a DED response marker. The methods of the present disclosure specifically include determining whether a particular individual has a DED response marker. This determination is made by identifying whether the patient has a DED response marker of Table 1. Each of these determinations (i.e., presence or absence) provides in itself the allelic status of the patient, and thus each of these determinations similarly provides an indication of whether a particular individual will respond better to TNFα antagonism.
[0027] [Table 1]
[0028] Table 1 shows various response alleles of the present disclosure. The first column provides the gene in which the SNP in the second column resides, and the third column provides the approximate location of that SNP in that gene.
[0029] The SNPs listed in Table 1 have predictive value with respect to TNFα antagonism when any of the given response alleles are present (i.e., whether the patient is homozygous or heterozygous for the given response allele), however, as discussed in the Examples below, patients with the CC genotype tended to have a greater improved response to LME636 compared to patients with the CT or TT genotypes.
[0030] The term "dry eye", also known as sicca conjunctivitis or sicca keratoconjunctivitis, is a common ophthalmic disorder involving breakdown of the anterior tear film and consequent loss of moisture on the exposed outer surface of the eye. In certain embodiments, "dry eye" is characterized as moderate to severe, with severity determined by those skilled in the art, for example, based on the Global Ocular Discomfort Score as described herein. Methods for determining the severity of dry eye are also described, for example, in the DEWS Definition and Classification Guidelines by the 2007 International Dry Eye Workshop (see "The Ocular Surface" April 2007, Vol. 5, No. 2, pages 75-92), or by Sullivan et al. (Investigative Ophthalmology & Visual Science, December 2010, Vol. 51, pg. 6125-6130).
[0031] The term "TNFα" refers to tumor necrosis factor alpha (also known as cachectin), which is a naturally occurring mammalian cytokine produced by many cell types, including monocytes and macrophages, in response to endotoxin or other stimuli. TNFα is a major mediator of inflammatory, immunological, and pathophysiological responses (Grell, M., et al. (1995) Cell, 83:793-802). "TNFα" includes wild-type TNFα, polymorphic variants of TNFα, and functional equivalents of TNFα from various species (e.g., human, mouse, and monkey). Functional equivalents of TNFα according to the present disclosure preferably have at least about 85%, 95%, 96%, 97%, 98%, or even 99% overall sequence identity with wild-type TNFα (e.g., human TNFα) and substantially retain the ability to mediate inflammatory, immunological, and pathophysiological responses.
[0032] "TNFα antagonist," as used herein, refers to a molecule capable of antagonizing (e.g., reducing, inhibiting, decreasing, delaying) TNFα function, expression, and / or signaling (e.g., by blocking the binding of TNFα to the TNFα receptor). Non-limiting examples of TNFα antagonists include TNFα binding molecules and TNFα receptor binding molecules. In some embodiments of the methods, regimens, kits, processes, uses, and compositions of the disclosure, TNFα antagonists are used.
[0033] By "TNFα binding molecule" is meant any molecule capable of binding to the human TNFα antigen, either alone or in association with another molecule. Binding responses may be demonstrated by standard methods (qualitative assays) or any type of binding assay, including, for example, binding assays that determine inhibition of TNFα binding to its receptor, competitive assays or bioassays, and against a negative control test using an antibody of irrelevant specificity, but ideally of the same isotype, e.g., an anti-CD25 antibody. Non-limiting examples of TNFα binding molecules include small molecules, TNFα receptor decoys, and antibodies that bind to TNFα as produced by B cells or hybridomas, and chimeric, CDR-grafted or human antibodies or any fragment thereof, e.g., F(ab') 2 and Fab fragments, as well as single chain or single domain antibodies. Preferably, the TNFα binding molecule antagonizes (e.g., reduces, inhibits, decreases, delays) TNFα function, expression and / or signaling. In some embodiments of the methods, regimens, kits, processes, uses and compositions of the disclosure, a TNFα binding molecule is used.
[0034] By "TNFα receptor binding molecule" is meant any molecule capable of binding to the human TNFα receptor, either alone or in association with another molecule. Binding responses may be demonstrated by standard methods (qualitative assays) or any type of binding assay, including, for example, binding assays that determine inhibition of binding of the TNFα receptor to TNFα, competitive assays or bioassays, and against negative control tests using antibodies of irrelevant specificity, but ideally of the same isotype. Non-limiting examples of TNFα receptor binding molecules include small molecules, TNFα decoys, and antibodies against the TNFα receptor as produced by B cells or hybridomas, and chimeric, CDR-grafted or human antibodies or any fragment thereof, such as F(ab') 2and Fab fragments, as well as single chain or single domain antibodies. Preferably, the TNFα receptor binding molecule antagonizes (e.g., reduces, inhibits, decreases, delays) TNFα function, expression and / or signaling. In some embodiments of the methods, regimens, kits, processes, uses and compositions of the disclosure, a TNFα receptor binding molecule is used.
[0035] The term "antibody" as referred to herein includes whole antibodies and any antigen-binding portion or single chains thereof. A naturally occurring "antibody" is a glycoprotein comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. Each heavy chain contains a heavy chain variable region (herein referred to as V H Each light chain comprises a light chain variable region (abbreviated herein as VL) and a heavy chain constant region. The heavy chain constant region comprises three domains, CH1, CH2 and CH3. Each light chain comprises a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region comprises one domain, CL. H and V L The regions can be further subdivided into regions of hypervariability called hypervariable or complementarity determining regions (CDRs) interspersed with regions that are more highly conserved called framework regions (FRs). H and V L comprises three CDRs and four FRs arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains comprise a binding domain that interacts with an antigen. The constant region of the antibody may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. In some embodiments of the methods, regimens, kits, processes, uses and compositions of the present disclosure, an antibody against TNFα or a TNFα receptor, preferably an antibody against TNFα, e.g., LME636, is used.
[0036] The term "antigen-binding portion" of an antibody, as used herein, refers to a fragment of an antibody that retains the ability to specifically bind to an antigen (e.g., TNFα). It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments that fall within the scope of the term "antigen-binding portion" of an antibody include V L , V H a Fab fragment, which is a monovalent fragment consisting of the CL and CH1 domains; a F(ab)2 fragment, which is a bivalent fragment containing two Fab fragments linked by a disulfide bridge at the hinge region; H and an Fd fragment consisting of the CH1 domain; L and V H Fv fragment consisting of domains; V H Exemplary antigen-binding sites include the CDRs of LME636, preferably the heavy chain CDR3, as set forth in SEQ ID NOs: 1-6 (Table 2). In addition, the two domains of the Fv fragment, the V L and V H Although encoded by separate genes, they can be joined together by synthetic linkers using recombinant methods to allow them to be made as a single protein chain, as herein defined as V L and V H The domains pair to form a monovalent molecule (known as a single chain Fv (scFv); see, e.g., Bird et al., 1988 Science 242:423-426; and Huston et al., 1988 Proc. Natl. Acad. Sci. 85:5879-5883). Such single chain antibodies are also intended to be included within the scope of the term "antibody". Single chain antibodies and antigen-binding portions are obtained using conventional techniques known to those of skill in the art. In some embodiments of the methods, regimens, kits, processes, uses, and compositions of the disclosure, single chain antibodies or antigen-binding portions of antibodies against TNFα (e.g., LME636) or against a TNFα receptor are used.
[0037] An "isolated antibody," as used herein, refers to an antibody that is substantially free of other antibodies having different antigen specificities (e.g., an isolated antibody that specifically binds TNFα is substantially free of antibodies that specifically bind antigens other than TNFα). The term "monoclonal antibody" or "monoclonal antibody composition," as used herein, refers to a preparation of antibody molecules of single molecular composition. The term "human antibody," as used herein, is intended to include antibodies having variable regions in which both the framework and CDR regions are derived from sequences of human origin. A "human antibody" need not be made by a human, human tissue, or human cell. A human antibody of the present disclosure may include amino acid residues not encoded by human sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro, by N-nucleotide addition at junctions during recombination of antibody genes in vivo, or by somatic mutation in vivo). In some embodiments of the methods, regimens, kits, processes, uses, and compositions of the present disclosure, the TNFα antagonist is a human antibody, an isolated antibody, and / or a monoclonal antibody. In other embodiments of the methods, regimens, kits, processes, uses and compositions of the disclosure, the TNFα antagonist is a recombinant single chain (scFv) antibody.
[0038] The term “K D " is intended to refer to the off-rate of a particular antibody-antigen interaction. D " as used herein means K d Against K a The ratio of (i.e., K d / K a ) and expressed as a molar concentration (M). D Values can be determined using methods well established in the art. DMethods for determining K are known in the art, for example using a biosensor system such as a Biacore® system. In some embodiments, a TNFα antagonist, e.g., a TNFα binding molecule (e.g., a TNFα antibody or antigen binding portion thereof, e.g., LME636) or a TNFα receptor binding molecule (e.g., a TNFα receptor antibody or antigen binding portion thereof), has a K of about 5 to 250 pM for human TNFα. D Combine with.
[0039] The term "affinity" refers to the strength of interaction between an antibody and an antigen at a single antigen site. Within each antigen site, the variable regions of the antibody "arms" interact with the antigen at multiple sites through weak non-covalent forces; the more interactions, the stronger the affinity. Standard assays for determining the binding affinity of antibodies to various species of TNFα are known in the art, including, for example, ELISA, Western blot, and RIA. The binding kinetics (e.g., binding affinity) of an antibody can also be evaluated by standard assays known in the art, such as by Biacore analysis.
[0040] It will be understood that an antibody that "inhibits" one or more of these TNFα functional properties (e.g., biochemical, immunochemical, cellular, physiological or other biological activity, etc.) as determined according to methodologies known in the art and described herein relates to a statistically significant decrease in the particular activity compared to that seen in the absence of the antibody (or in the presence of a control antibody of irrelevant specificity). Antibodies that inhibit TNFα activity will, for example, affect a statistically significant decrease of at least about 10%, at least 50%, 80% or 90% of the measured parameter, and in certain embodiments of the methods, uses, processes, kits and compositions of the present disclosure, the TNFα antibodies used may inhibit greater than 95%, 98% or 99% of TNFα functional activity.
[0041] The term "derivative" is used to define amino acid sequence variants, and covalent modifications (e.g., pegylation, deamidation, hydroxylation, phosphorylation, methylation, etc.) of a TNFα antagonist, e.g., TNFα binding molecule (e.g., a TNFα antibody or antigen-binding portion thereof, e.g., LME636) or TNFα receptor binding molecule (e.g., a TNFα receptor antibody or antigen-binding portion thereof) according to the present disclosure, e.g., of a specified sequence (e.g., variable domain), unless otherwise indicated. "Functional derivatives" include molecules that have qualitative biological activity in common with a TNFα antagonist, e.g., a TNFα binding molecule, of the present disclosure. Functional derivatives include fragments and peptide analogs of TNFα antagonists as disclosed herein. Fragments include regions within the sequence of a polypeptide according to the present disclosure, e.g., of a specified sequence. Functional derivatives of TNFα antagonists disclosed herein (e.g., a functional derivative of LME636) preferably include the V domain of a TNFα binding molecule disclosed herein. H and / or V L Sequence (e.g., V in Table 2 H and / or V L sequence) having at least about 65%, 75%, 85%, 95%, 96%, 97%, 98%, or even 99% overall sequence identity with H and / or V L domain and substantially retains the ability to bind to human TNFα.
[0042] The phrase "substantially identical" refers to a related amino acid or nucleotide sequence (e.g., H Or V L This means that a specified region (e.g., a V domain) will be identical or have only insubstantial differences (e.g., by conservative amino acid substitutions) compared to a particular reference sequence. Insubstantial differences include those that are not identical to a specified region (e.g., a V domain) or that have only insubstantial differences (e.g., by conservative amino acid substitutions) compared to a particular reference sequence. H Or V LThe second antibody may have minor amino acid changes such as one or two substitutions (e.g., conservative substitutions such as swapping serine for threonine, or substitutions at positions not involved in antibody activity, structural integrity, complement binding, etc.) in the five amino acid sequence of the second antibody (domain). In the case of an antibody, the second antibody has the same specificity and at least 50% of its affinity. Sequences substantially identical (e.g., at least about 85% sequence identity) to the sequences disclosed herein are also part of the disclosure. In some embodiments, the sequence identity of a derivative TNFα antibody (e.g., a derivative of LME636, e.g., a LME636 biosimilar antibody) may be about 90% or more, e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more, based on the sequences disclosed herein.
[0043] "Identity," with respect to naturally occurring polypeptides and their functional derivatives, is defined herein as the percentage of amino acid residues in a candidate sequence that are identical to those of the corresponding naturally occurring polypeptide, after aligning the sequences and introducing gaps, if necessary, so that the maximum percent identity is achieved, and without considering any conservative substitutions as part of the sequence identity. Neither N- or C-terminal extensions nor insertions shall be construed as reducing identity. Alignment methods and computer programs are well known. Percent identity can be determined by standard alignment algorithms, such as the Basic Local Alignment Search Tool (BLAST) described by Altshul et al. ((1990) J. Mol. Biol., 215:403 410); the algorithm of Needleman et al. ((1970) J. Mol. Biol., 48:444 453); or the algorithm of Meyers et al. ((1988) Comput. Appl. Biosci., 4:11 17). The set of parameters may be a Blosum 62 scoring matrix, with a gap penalty of 12, a gap extension penalty of 4, and a frameshift gap penalty of 5. The percent identity between two amino acid or nucleotide sequences can also be determined using the algorithm of E. Meyers and W. Miller ((1989) CABIOS, 4:11-17) incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4.
[0044] "Amino acid" refers to any naturally occurring L-α-amino acid, for example, and includes D-amino acids. The phrase "amino acid sequence variant" refers to a molecule that has some difference in its amino acid sequence when compared to the sequences of the present disclosure. For example, an amino acid sequence variant of a polypeptide of the present disclosure of a specified sequence still has the ability to bind human TNFα. Amino acid sequence variants include substitution variants (wherein at least one amino acid residue has been removed from the polypeptide of the present disclosure and another amino acid has been inserted in its place at the same position), insertion variants (wherein one or more amino acids have been inserted immediately adjacent to an amino acid at a particular position in the polypeptide of the present disclosure), and deletion variants (wherein one or more amino acids have been removed from the polypeptide of the present disclosure).
[0045] The term "pharmacologically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s).
[0046] The term "administering" with respect to a compound, such as a TNFα binding molecule or another agent, is used to refer to delivering the compound to a patient by any route.
[0047] As used herein, a "therapeutically effective amount" refers to an amount of a TNFα antagonist, e.g., a TNFα binding molecule (e.g., a TNFα antibody or antigen binding portion thereof, e.g., LME636) or a TNFα receptor binding molecule (e.g., a TNFα receptor antibody or antigen binding portion thereof), effective upon administration in single or multiple doses to a patient (such as a human) to treat, prevent, prevent the onset of, cure, delay, reduce the severity of, ameliorate at least one symptom of a disorder or a recurrent disorder, or to prolong the survival of a patient beyond expected survival in the absence of such treatment. When applied to individual active ingredients (e.g., a TNFα antagonist, e.g., LME636) administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to the combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, sequentially, or simultaneously.
[0048] The term "treatment" or "treating" refers to both prophylactic or preventative treatment (as the case may be) as well as curative or disease-modifying treatment, including treatment of patients at risk for or suspected of having a disease as well as patients diagnosed with a disease or condition, and includes the suppression of clinical recurrence. Treatment may be administered to a patient who has a medical disorder or who may ultimately acquire a disorder in order to prevent, cure, delay the onset of, reduce the severity of, or ameliorate one or more symptoms of a disorder or recurrent disorder, or to prolong the survival of the patient beyond that expected in the absence of such treatment.
[0049] The phrase "responds to treatment" is used to mean that upon delivery of a particular treatment, such as a TNFα binding molecule (e.g., LME636), the patient shows a clinically meaningful benefit from said treatment. In the case of DED, such criteria include, for example, an improvement in the overall eye discomfort score. All such criteria are acceptable measures of whether a patient is responding to a given treatment. The phrase "responds to treatment" is intended to be interpreted comparatively rather than as an absolute response. For example, DED patients with DED response markers are predicted to have more benefit from treatment with TNFα antagonists than DED patients without DED response markers. These DED response marker carriers respond better to treatment with TNFα antagonists and can simply be said to "respond to treatment" with TNFα antagonists.
[0050] The phrase "receive data" is used to mean obtaining information in possession by any available means, such as orally, electronically (e.g., by email, encoded on a diskette or other medium), in writing, etc.
[0051] As used herein, "select" and "selected" with respect to a patient are used to mean that a particular patient is specially selected from a larger patient population based on (or due to) that particular patient has a certain criterion, for example, that the patient has a DED response marker. Similarly, "selectively treating" refers to providing treatment to a patient with DED, where the patient is specially selected from a larger patient population based on (or due to) that particular patient has a certain criterion, for example, a DED patient is specially selected for treatment because the patient has a DED response marker. Similarly, "selectively administering" refers to administering a drug to a patient who is specially selected from a larger patient population based on (or due to) that particular patient has a certain criterion, for example, a particular genetic or other biological marker. Selecting, selectively treating, and selectively administering refer to delivering an individualized therapy to a patient based on the patient's particular biology, rather than delivering a standard treatment regimen based solely on the patient having DED. As used herein, selective treatment does not refer to the chance treatment of a patient who has a DED response marker, but rather to the deliberate selection of administering a TNFα antagonist to a patient based on the patient having a DED response marker. Thus, selective treatment differs from standard treatment, which delivers a particular drug to all patients regardless of their allelic status.
[0052] As used herein, "predict" refers to the methods described herein providing information that allows a health care provider to determine the likelihood that an individual with DED will respond, or even better, to treatment with a TNFα binding molecule. This does not refer to being able to predict response with 100% accuracy. Instead, one of skill in the art will understand that this refers to an increase in probability.
[0053] As used herein, "possibility" and "likely" are measures of how likely an event is to occur. They may be used synonymously with "probability." Possibility refers to a probability that exceeds guesswork but does not amount to certainty. Thus, an event is likely when a reasonable person using common sense, training, or experience would conclude that an event is likely, given the circumstances. In some embodiments, once a probability is established, the patient may be treated with the TNFα binding molecule (or treatment may be continued, or treatment may be moved to an increased dosage), or the patient may not be treated (or treatment may be discontinued, or treatment may be moved to a lower dose).
[0054] The phrase "increased likelihood" refers to an increased probability that an event will occur. For example, some methods herein allow for prediction of whether a patient will show an increased likelihood of responding to treatment with a TNFα binding molecule, or an increased likelihood of responding better to treatment with a TNFα binding molecule compared to DED patients who do not have a DED response marker.
[0055] As used herein, "SNP" refers to "single nucleotide polymorphism." A single nucleotide polymorphism is a DNA sequence variation that occurs when a single nucleotide in a genome (or other shared sequence) differs between members of a biological species or between paired chromosomes in an individual. Most SNPs have only two alleles, one of which is usually more prevalent in a population. SNPs can occur in the exons or introns of a gene, in untranslated regions upstream or downstream of a gene, or simply in a genomic location (i.e., not transcribed). When a SNP occurs in a coding region of a gene, the SNP may be silent due to redundancy in the genetic code (i.e., a synonymous polymorphism), or the SNP may result in a change in the sequence of the encoded polypeptide (i.e., a nonsynonymous polymorphism). In this disclosure, a SNP is identified by its Single Nucleotide Polymorphism Database (dbSNP) rs number, e.g., "rs1800693." dbSNP is a free, public archive of genetic variation within and among various species, developed and maintained by the National Center for Biotechnology Information (NCBI) in collaboration with the National Human Genome Research Institute (NHGRI).
[0056] Polymorphic sites, such as SNPs, are usually preceded and followed by conserved sequences in the genome of a population of interest, and thus the location of a polymorphic site can often be determined based on a consensus nucleic acid sequence (e.g., 30-60 nucleotides) surrounding the polymorphic site, commonly referred to in the case of SNPs as the "SNP context sequence." Context sequences for SNPs disclosed herein may be referenced to the NCBI SNP database available at www.ncbi.nlm.nih.gov / snp. Alternatively, the location of a polymorphic site may be identified by its location on a reference sequence (e.g., a GeneBank deposit) relative to the beginning of a gene, mRNA transcript, BAC clone, or even relative to the start codon (ATG) of protein translation. One of skill in the art will appreciate that the location of a particular polymorphic site in each individual in a population of interest may not be at the exact same location of the reference or context sequence due to the presence of one or more insertions or deletions in the genome of that individual as compared to the consensus or reference sequence. It is routine for a person skilled in the art to design a robust, specific and accurate assay for detecting alternative alleles of a polymorphic site in any given individual when the person skilled in the art is provided with the identity of the alternative allele at the polymorphic site to be detected and either or both of the reference sequence or the context sequence in which the polymorphic site is present.Thus, the person skilled in the art will understand that it is merely for convenience to specify the location of any polymorphic site described herein by reference to a particular position in the reference sequence or the context sequence (or relative to the start codon of such sequence), and that any specifically recited nucleotide position literally includes any nucleotide position where the same polymorphic site is actually located at the same locus in any individual tested for the genetic marker of the present invention using any of the genotyping methods described herein or other genotyping methods known in the art.
[0057] In addition to SNPs, genetic polymorphisms include translocations, insertions, substitutions, deletions, and the like that occur in gene enhancers, exons, introns, promoters, 5'UTRs, 3'UTRs, and the like.
[0058] As used herein, "rs1800693" refers to a T / C SNP located within the sixth intron of the human tumor necrosis factor receptor superfamily, member 1A (TNFRSF1A) gene (GenBank accession number NM_001065.3), also known as tumor necrosis factor receptor 1 (TNFR1). The TNFRSF1A protein is one of the major TNFα receptors and is involved in the NF-κB pathway, mediating apoptosis and regulating inflammation. The rs1800693 polymorphic site is located at chromosome 12:6330843. The phrase "rs1800693-responsive allele" as used herein refers to the "C" allele (G allele for the non-coding strand) or the "T" allele (A allele for the non-coding strand) at the rs1800693 polymorphic site. In some embodiments of the methods, uses, and kits of the present disclosure, the patient has at least one rs1800693-responsive allele.
[0059] The above-mentioned response alleles are useful for predicting the response of DED patients to TNFα antagonism. In some embodiments, DED patients with CC, CT, or TT genotypes are considered likely to respond to treatment with a TNFα antagonist, e.g., a TNFα antibody such as LME636.
[0060] As those skilled in the art will recognize, the nucleic acid sample containing a particular SNP may be a complementary double-stranded molecule, and therefore a reference to a particular site on the sense strand is also a reference to the corresponding site on the complementary antisense strand.Similarly, a reference to a particular genotype obtained for a SNP on both copies of one strand of a chromosome is equivalent to the complementary genotype obtained for the same SNP on both copies of the other strand.Thus, for example, the T / C genotype for the rs1800693 polymorphic site on the coding strand is equivalent to the A / G genotype for the same polymorphic site on the non-coding strand.
[0061] As used herein, "genomic sequence" refers to a DNA sequence present in a genome, including a region within an allele, the allele itself, or the larger DNA sequence of a chromosome that contains the allele of interest.
[0062] Products of a DED responsive marker include nucleic acid products and polypeptide products. "Polypeptide product" refers to a polypeptide encoded by a DED responsive marker and fragments thereof. "Nucleic acid product" refers to any DNA (e.g., genomic DNA, cDNA, etc.) or RNA (e.g., pre-mRNA, mRNA, miRNA, etc.) product of a DED responsive marker and fragments thereof.
[0063] "Equivalent genetic marker" refers to a genetic marker that correlates with an allele of interest, e.g., that exhibits linkage disequilibrium (LD) or is genetically linked to the allele of interest. Rather than directly testing a biological sample from the patient for the allele itself to determine whether a patient has a DED response marker, an equivalent genetic marker may be used. Various programs exist that assist in the determination of LD for particular SNPs, e.g., HaploBlock (available at bioinfo.cs.technion.ac.il / haploblock / ), HapMap, and WGA Viewer.
[0064] The term "probe" refers to any composition of matter useful for specifically detecting another substance, for example, a substance related to a DED response marker. A probe may be an oligonucleotide (including a conjugated oligonucleotide) that specifically hybridizes to a genomic sequence of a DED response marker or a nucleic acid product of a DED response marker. A conjugated oligonucleotide refers to an oligonucleotide that is covalently attached to a chromophore or a molecule that contains a highly specific ligand (e.g., an antigen) for a receptor molecule (e.g., an antibody specific for that antigen). A probe may also be a PCR primer, for example, together with another primer, for amplifying a specific region within a DED response marker. Furthermore, a probe may be an antibody that specifically binds to a polypeptide product of these alleles. Furthermore, a probe may be any composition of matter capable of detecting (e.g., binding or hybridizing to) an equivalent genetic marker of a DED response marker. In a preferred embodiment, the probe specifically hybridizes to a nucleic acid sequence (preferably genomic DNA) of an allele of interest or specifically binds to a polypeptide sequence.
[0065] The phrase "specifically hybridize" is used to refer to hybridization under stringent hybridization conditions. Stringent conditions are known to those skilled in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, NY (1989), 6.3.1-6.3.6. Aqueous and non-aqueous methods are described in the literature and either can be used. An example of stringent hybridization conditions is hybridization in 6x sodium chloride / sodium citrate (SSC) at about 45°C, followed by at least one wash in 0.2x SSC, 0.1% SDS at 50°C. A second example of stringent hybridization conditions is hybridization in 6x SSC at about 45°C, followed by at least one wash in 0.2x SSC, 0.1% SDS at 55°C. Another example of stringent hybridization conditions is hybridization in 6×SSC at about 45° C., followed by at least one wash in 0.2×SSC, 0.1% SDS at 60° C. A further example of stringent hybridization conditions is hybridization in 6×SSC at about 45° C., followed by at least one wash in 0.2×SSC, 0.1% SDS at 65° C. Highly stringent conditions include hybridization in 0.5 M sodium phosphate, 7% SDS at 65° C., followed by at least one wash in 0.2×SSC, 1% SDS at 65° C.
[0066] The phrase "region of a nucleic acid" is used to refer to a smaller sequence within a larger nucleic acid sequence, e.g., a gene is a region of a chromosome, an exon is a region of a gene, etc.
[0067] The term "specifically binds" in the context of a polypeptide is used to mean that the probe binds to a given polypeptide target (e.g., a polypeptide product of a DED responsive marker) rather than randomly binding to undesired polypeptides. However, "specifically binds" does not exclude some cross-reactivity with undesired polypeptides, so long as such cross-reactivity does not interfere with the ability of the probe to provide a useful measurement of the presence of the given polypeptide target.
[0068] The term "capable of" is used to mean capable of achieving a given result, for example, a probe capable of detecting the presence of a particular substance means that the probe can be used to detect the particular substance.
[0069] "Oligonucleotide" refers to a short nucleotide sequence, for example, between 2 and 100 bases.
[0070] The term "biological sample" as used herein refers to a sample from a patient that can be used for identification, diagnosis, prognosis, or monitoring.Preferred samples include synovial fluid, blood, blood-derived products (such as buffy coat, serum, and plasma), lymph, urine, tears, saliva, hair bulb cells, cerebrospinal fluid, buccal swabs, feces, synovial fluid, synovial cells, sputum, or tissue samples (such as cartilage samples).In addition, those skilled in the art will understand that some samples may be easier to analyze after fractionation or purification procedures, such as after isolating DNA from whole blood.
[0071] TNFα antagonists The various pharmaceutical compositions, regimens, processes, uses, methods and kits disclosed utilize a TNFα antagonist, such as a TNFα binding molecule (e.g., a TNFα antibody or antigen-binding portion thereof, e.g., LME636) or a TNFα receptor binding molecule (e.g., a TNFα receptor antibody or antigen-binding portion thereof).
[0072] In one embodiment, a TNFα antagonist, e.g., a TNFα binding molecule (e.g., a TNFα antibody or antigen-binding portion thereof, e.g., LME636), comprises at least one heavy chain variable domain (VH) comprising hypervariable regions CDRH1, CDRH2, and CDRH3. H ), wherein the CDRH1 has the amino acid sequence SEQ ID NO:1, the CDRH2 has the amino acid sequence SEQ ID NO:2, and the CDRH3 has the amino acid sequence SEQ ID NO:3. In one embodiment, the TNFα antagonist, e.g., a TNFα binding molecule (e.g., a TNFα antibody or antigen binding portion thereof, e.g., LME636), comprises at least one light chain variable domain (V) comprising hypervariable regions CDRL1, CDRL2, and CDRL3. L ), wherein CDRL1 has the amino acid sequence SEQ ID NO:4, CDRL2 has the amino acid sequence SEQ ID NO:5, and CDRL3 has the amino acid sequence SEQ ID NO:6.
[0073] In one embodiment, a TNFα antagonist, e.g., a TNFα binding molecule (e.g., a TNFα antibody or antigen-binding portion thereof, e.g., LME636) is H Domain and V L domain, where: a) V H The domain comprises (e.g., in sequence): i) hypervariable regions CDRH1, CDRH2 and CDRH3, said CDRH1 having the amino acid sequence SEQ ID NO:1, said CDRH2 having the amino acid sequence SEQ ID NO:2, and said CDRH3 having the amino acid sequence SEQ ID NO:3; and b) V L The domain comprises (eg, in sequence) hypervariable regions CDRL1, CDRL2 and CDRL3, said CDRL1 having the amino acid sequence SEQ ID NO:4, said CDRL2 having the amino acid sequence SEQ ID NO:5, and said CDRL3 having the amino acid sequence SEQ ID NO:6.
[0074] In one embodiment, a TNFα antagonist, e.g., a TNFα binding molecule (e.g., a TNFα antibody or antigen-binding portion thereof, e.g., LME636), comprises a) a heavy chain variable domain (V) comprising the amino acid sequence set forth as SEQ ID NO:8. H ); b) a light chain variable domain (VL c) V comprising the amino acid sequence shown as SEQ ID NO:8 H V domain and the amino acid sequence shown as SEQ ID NO: 10 L domain; d) V domains including hypervariable regions shown as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 H e) V domains including hypervariable regions shown as SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6 L or f) a V domain comprising the hypervariable regions shown as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3. H V domain and hypervariable regions shown as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6 L Includes the domain.
[0075] For ease of reference, the amino acid sequences of the hypervariable regions of the LME636 scFv antibody are provided in Table 2 below.
[0076] [Table 2]
[0077] In some embodiments, the TNFα antagonist, e.g., a TNFα binding molecule (e.g., a TNFα antibody or antigen binding portion thereof, e.g., LME636), comprises a light chain of SEQ ID NO: 7. In other embodiments, the TNFα antagonist comprises a heavy chain of SEQ ID NO: 8. In other embodiments, the TNFα 7 antagonist comprises a light chain of SEQ ID NO: 7 and a heavy chain of SEQ ID NO: 8. In some embodiments, the TNFα antagonist comprises the three CDRs of SEQ ID NO: 7. In other embodiments, the TNFα antagonist comprises the three CDRs of SEQ ID NO: 8. In other embodiments, the TNFα antagonist comprises the three CDRs of SEQ ID NO: 7 and the three CDRs of SEQ ID NO: 8. The CDRs of SEQ ID NO: 7 and SEQ ID NO: 8 are set forth in Table 2. In other embodiments, the TNFα antagonist comprises the sequence of SEQ ID NO: 9: [ka]
[0078] The hypervariable region may involve any type of framework region, but is preferably of human origin. Suitable framework regions are described in Kabat EA et al., supra. A preferred heavy chain framework is the heavy chain framework of the LME636 antibody as shown in SEQ ID NO: 10: [ka]
[0079] A preferred light chain framework is the light chain framework of the LME636 antibody as shown in SEQ ID NO: 11: [ka]
[0080] When used in the sequences of SEQ ID NO: 10 and SEQ ID NO: 11, (X) n=3-50 represents the CDRs.
[0081] In one embodiment, the TNFα antagonist, e.g., a TNFα binding molecule (e.g., a TNFα antibody or antigen binding portion thereof, e.g., LME636), is selected from a) a first domain comprising in sequence hypervariable regions CDRH1, CDRH2 and CDRH3, wherein CDRH1 has the amino acid sequence SEQ ID NO:1, wherein CDRH2 has the amino acid sequence SEQ ID NO:2, and wherein CDRH3 has the amino acid sequence SEQ ID NO:3; and b) a second domain comprising hypervariable regions CDRL1, CDRL2 and CDRL3, wherein CDRL1 has the amino acid sequence SEQ ID NO:4, wherein CDRL2 has the amino acid sequence SEQ ID NO:5, and wherein CDRL3 has the amino acid sequence SEQ ID NO:6; and c) an antigen binding site comprising a peptide linker connecting either the N-terminal end of the first domain and the C-terminal end of the second domain or the C-terminal end of the first domain and the N-terminal end of the second domain.
[0082] Alternatively, the TNFα antagonist, e.g., TNFα binding molecule (e.g., a TNFα antibody or antigen-binding portion thereof) used in the methods of the present disclosure may comprise a derivative of the TNFα binding molecule depicted by the sequence (e.g., a pegylated version of LME636). Alternatively, the V of the TNFα antagonist, e.g., TNFα binding molecule (e.g., a TNFα antibody or antigen-binding portion thereof) used in the methods of the present disclosure may comprise a derivative of the TNFα binding molecule depicted by the sequence (e.g., a pegylated version of LME636). H Or V L The domains are V H Or V L V domains substantially identical to those shown in SEQ ID NOs: 8 and 7. H Or V L The anti-TNFα antibodies disclosed herein may comprise a heavy chain substantially identical to that set forth as SEQ ID NO:8 and / or a light chain substantially identical to that set forth as SEQ ID NO:7. The anti-TNFα antibodies disclosed herein may comprise a heavy chain comprising SEQ ID NO:8 and a light chain comprising SEQ ID NO:7. The anti-TNFα antibodies disclosed herein may comprise a) one heavy chain comprising a variable domain having substantially the same amino acid sequence as set forth in SEQ ID NO:8 and a constant portion of a human heavy chain; and b) one light chain comprising a variable domain having substantially the same amino acid sequence as set forth in SEQ ID NO:7 and a constant portion of a human light chain. Alternatively, the TNFα antagonist, e.g., TNFα binding molecule (e.g., a TNFα antibody or antigen-binding portion thereof) used in the methods of the present disclosure may be an amino acid sequence variant of a reference TNFα binding molecule set forth herein. In all such exemplary derivatives and variants, the TNFα antagonists have the ability to inhibit the activity of human TNFα at about 1 nM (= 30 ng / ml) by 50% at a concentration of the molecule of about 50 nM or less, about 20 nM or less, about 10 nM or less, about 5 nM or less, or more preferably about 3 nM or less, said inhibitory activity being measured, for example, by assaying for neutralization of TNFα cytotoxicity of L929 cells as described in Chiu et al., 2011, PLoS ONE, Vol 6, issue 1, e16373.
[0083] The disclosure may also include TNFα antagonists, e.g., TNFα binding molecules (e.g., TNFα antibodies or antigen-binding portions thereof, e.g., LME636), in which one or more, typically only a few (e.g., 1-4), of CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, CDRL3, or framework amino acid residues have been altered, e.g., by mutation, e.g., site-directed mutagenesis, of the corresponding DNA sequence. The disclosure includes DNA sequences encoding such altered TNFα antagonists.
[0084] The present disclosure also includes TNFα antagonists having binding specificity for human TNFα, such as TNFα binding molecules (e.g., TNFα antibodies or antigen-binding portions thereof, e.g., LME636), in particular TNFα antibodies having the ability to inhibit the binding of TNFα to its receptor and TNFα antibodies having the ability to inhibit the activity of 1 nM (=30 ng / ml) human TNFα by 50% at a concentration of said molecule of about 50 nM or less, about 20 nM or less, about 10 nM or less, about 5 nM or less, or more preferably about 3 nM or less, said inhibitory activity being measured by assaying for neutralization of TNFα cytotoxicity of L929 cells.
[0085] In a preferred embodiment, the anti-TNFα antibody used in the disclosed methods, uses, kits, etc. is LME636, which comprises the sequence of SEQ ID NO: 9. LME636 is a humanized monoclonal scFv antibody fragment consisting of 254 amino acids (molecular mass: 26.7 kDa) that inhibits human TNFα and is recombinantly produced in E. coli by standard expression techniques. This molecule was engineered by grafting the complementarity determining regions (CDRs) and specific framework residues from the light and heavy chain variable region sequences of a monoclonal rabbit anti-human TNFα antibody onto human light and heavy chain variable region frameworks, covalently linked by flexible amino acid sequences consisting of glycine and serine.
[0086] In one embodiment, the methionine from the start codon in the expression vector is present in the final protein if it is not cleaved post-translationally, in which case LME636 has the sequence of SEQ ID NO: 12: [ka]
[0087] Other preferred TNFα antibodies for use in the methods, kits and uses of the disclosure are those set out in WO 2009 / 155723 and WO 2012 / 051734.
[0088] Assay techniques, diagnostic methods and methods for producing information in a transmissible form The methods of the disclosure are useful for treating or ameliorating DED, as well as predicting the likelihood of a DED patient responding to treatment with a TNFα antagonist, such as LME636. These methods employ, inter alia, determining whether a patient has a DED response marker in a sample from the patient.
[0089] Biological samples from patients may be assayed for the presence of DED response markers by any applicable conventional means, which will be selected depending on whether the particular marker is within an exon, an intron, a non-coding portion of an mRNA, or a non-coding genomic sequence.
[0090] Numerous biological samples, such as blood, synovial fluid, buffy coat, serum, plasma, lymph, feces, urine, tears, saliva, cerebrospinal fluid, buccal swabs, sputum, or tissue, can be used to identify the presence of alleles or proteins, gene or protein expression levels, and protein activity. Various sources within the biological sample can be used in the methods of the present disclosure, for example, genomic DNA obtained from the biological sample can be assayed to detect DED response markers, or products of the DED response markers obtained from the biological sample, such as nucleic acid products (e.g., DNA, pre-mRNA, mRNA, microRNA, etc.) and polypeptide products (e.g., expressed proteins).
[0091] The inventors have determined that the various SNP alleles of Table 1 are useful for predicting a particular patient's responsiveness to treatment with TNFα antagonism (e.g., with LME636). In a preferred embodiment, the genomic sequence of the DED response marker is analyzed to determine whether a subject has the DED response marker.
[0092] As described in the Examples, the current findings of the present inventors lead to the conclusion that the presence of genotypes associated with SNP rs1800693 may be useful for predicting improved response to TNFα antagonism (e.g., LME636) for DED. The presence of DED response markers can be detected by various genotyping techniques. Typically, such genotyping techniques utilize one or more oligonucleotides that are complementary to the region that contains or is adjacent to the polymorphic site of interest (e.g., SNP). The sequence of the oligonucleotide used for genotyping a particular polymorphic site of interest is typically designed based on a context sequence or a reference sequence.
[0093] Numerous methods and devices are available for identifying the presence of DED-responsive markers. DNA (genomic DNA and cDNA) for SNP detection can be prepared from biological samples by methods well known in the art, such as phenol / chloroform extraction, PUREGENE DNA® purification system from GentAS Systems (Qiagen, CA). Detection of DNA sequences can include examining one or more nucleotides located in either the sense or antisense strand within the region of interest. The presence of polymorphisms in patients can be detected from the resulting DNA (genomic DNA or cDNA) by PCR using sequence-specific probes, such as hydrolysis probes from Taqman, Beacons, Scorpions; or hybridization probes that detect the marker or polymorphism. For detection of polymorphisms, sequence-specific probes can be designed so that they hybridize specifically to the genomic DNA of the allele of interest, or in some cases, the RNA of interest. Primers and probes for polymorphic sites (e.g., SNPs) can be designed based on context sequences listed in the NCBI SNP database available at www.ncbi.nlm.nih.gov / snp. These probes may be labeled for direct detection or may be contacted with a secondary detectable molecule that specifically binds to the probe. PCR products may also be detected by DNA binding agents. The PCR products may then be subsequently sequenced by any DNA sequencing method available in the art. Alternatively, the presence of alleles may be detected by sequencing using any sequencing method, including but not limited to Sanger-based sequencing, pyrosequencing or next-generation sequencing (Shendure J. and Ji, H., Nature Biotechnology (1998), Vol. 26, Nr 10, pages 1135-1145). SNP-optimized allele discrimination assays may be purchased from Applied Biosystems (Foster City, California, USA).
[0094] To investigate specific polymorphisms (e.g. SNPs), for example, hybridization-based methods such as Dynamic Allele-Specific Hybridization (DASH) genotyping, polymorphic site (e.g. SNP) detection by molecular beacons (Abravaya K., et al. (2003) Clin Chem Lab Med. 41:468-474), Luminex xMAP technology, Illumina Golden Gate technology and commercially available high-density oligonucleotide SNP arrays (e.g., the Affymetrix Human SNP5.0 GeneChip implements a genome-wide assay capable of genotyping over 500,000 human SNPs), BeadChip kits from Illumina, such as the Human660W-Quad and Human 1.2M-Duo; enzyme-based methods such as restriction fragment length polymorphism (RFLP), PCR-based methods (e.g., tetra-primer ARMS-PCR), Invader assay (Olivier M. (2005) Mutat Res. 573(1-2):103-10), various primer extension assays (incorporated into detection formats such as MALDI-TOF mass spectrometry, electrophoresis, blotting, and ELISA-like methods), TaqMan® assays, and oligonucleotide ligase assays; and other post-amplification methods such as single-strand conformation polymorphism analysis (Costabile et al. (2006) Hum. Mutat.27(12):1163-73), temperature gradient gel electrophoresis (TGGE), denaturing high performance liquid chromatography, high resolution melting analysis, DNA mismatch binding protein assays (e.g., the MutS protein of Thermus aquaticus binds different single nucleotide mismatches with different affinities and can distinguish all six mismatch sets when used in capillary electrophoresis), SNPLex® (a proprietary SNP detection system available from Applied Biosystems), capillary electrophoresis, mass spectrometry, and various sequencing methods such as pyrosequencing and next generation sequencing. Commercially available kits for SNP gene typing include, for example, Fluidigm Dynamic Array (registered trademark) IFC (Fluidigm), TaqMan (registered trademark) SNP gene typing assay (Applied Biosystems), MassARRAY (registered trademark) iPLEX Gold (Sequenom), and Type-it Fast (registered trademark) SNP probe PCR kit (Quiagen).
[0095] In some embodiments, the presence of a polymorphic site (e.g., SNP) in a patient is detected using a hybridization assay. In a hybridization assay, the presence of a genetic marker is determined based on the ability of a nucleic acid from a sample to hybridize to a complementary nucleic acid molecule, e.g., an oligonucleotide probe. A variety of hybridization assays are available. In some, hybridization of a probe to a sequence of interest is detected directly by visualization of the bound probe, e.g., Northern or Southern assay. In these assays, DNA (Southern) or RNA (Northern) is isolated. The DNA or RNA is then cleaved with a series of restriction enzymes that cut at low frequency in the genome and do not cut near any of the markers being assayed. The DNA or RNA is then separated, e.g., on an agarose gel and transferred to a membrane. One or more labeled probes, e.g., by incorporating a radionucleotide or binding agent (e.g., SYBR® Green), are contacted with the membrane under low, medium, or high stringency conditions. Unbound probes are removed and the presence of binding is detected by visualization of the labeled probes. In some embodiments, subjects may be genotyped using an array, such as the MassARRAY® system (Sequenom, San Diego, California, USA).
[0096] Conventional genotyping methods may also be modified for use in genotyping, including, for example, DNA amplification techniques such as PCR and its variations, direct sequencing, SSO hybridization in combination with Luminex xMAP® technology, SSP typing, and SBT.
[0097] Sequence-Specific Oligonucleotide (SSO) typing uses PCR target amplification, hybridization of the PCR products to a panel of sequence-specific oligonucleotides immobilized on beads, detection of probe-bound amplification products by color development, and subsequent data analysis. Those skilled in the art will appreciate that the described sequence-specific oligonucleotide (SSO) hybridization may be performed using a variety of commercially available kits, such as those provided by One Lambda, Inc. (Canoga Park, CA) or the Lifecodes HLA Typing Kit (Tepnel Life Sciences Corp.) in combination with Luminex® technology (Luminex, Corporation, TX). LABType® SSO is a reverse SSO (rSSO) DNA typing solution that uses sequence-specific oligonucleotide (SSO) probes and color-coded microspheres to identify HLA alleles. Target DNA is amplified by polymerase chain reaction (PCR) and then hybridized to a bead probe array. The assay is performed in a single well of a 96-well PCR plate; therefore, 96 samples can be processed at once.
[0098] Sequence Specific Primers (SSP) typing is a PCR-based technique that uses sequence-specific primers for DNA-based typing. The SSP method is based on the principle that under controlled PCR conditions, only primers with a perfect sequence match to the target sequence will result in an amplification product. An allele sequence-specific primer pair is designed to selectively amplify a target sequence specific to a single allele or a population of alleles. The PCR product can be visualized on an agarose gel. A control primer pair that matches a non-allelic sequence present in all samples serves as an internal PCR standard to verify PCR amplification efficiency. Those skilled in the art will understand that low, medium and high resolution genotyping by sequence specific primer typing as described may be performed using various commercially available kits, such as the Olerup SSP™ kit (Olerup, PA) or (Invitrogen) or Allset and™ Gold DQA1 low resolution SSP (Invitrogen).
[0099] Sequence Based Typing (SBT) is based on PCR target amplification followed by sequencing of the PCR products and data analysis.
[0100] In some cases, RNA, such as mature mRNA, pre-mRNA, can also be used to determine the presence of a particular polymorphism (see Table 1). Analysis of the sequence of mRNA transcribed from a given gene can be performed using any method known in the art, including, but not limited to, Northern blot analysis, nuclease protection assay (NPA), in situ hybridization, reverse transcription polymerase chain reaction (RT-PCR), RT-PCR ELISA, TaqMan-based quantitative RT-PCR (probe-based quantitative RT-PCR) and SYBR green-based quantitative RT-PCR. In one example, detecting mRNA levels includes contacting the isolated mRNA with an oligonucleotide that can hybridize to the mRNA encoded by the DED-responsive marker. The nucleic acid probe can typically be a full-length cDNA or a portion thereof sufficient to specifically hybridize to the mRNA under stringent conditions, such as an oligonucleotide of at least 7, 15, 30, 50, or 100 nucleotides in length. Hybridization of the mRNA with the probe indicates that the marker of interest is expressed. In one format, the RNA is immobilized on a solid surface and contacted with the probe, for example by running the isolated RNA on an agarose gel and transferring the mRNA from the gel to a membrane such as nitrocellulose. Amplification primers are defined as a pair of nucleic acid molecules that anneal to the 5' or 3' region of a gene (the plus and minus strands, respectively, or vice versa) and can include a short region between them. Generally, amplification primers are about 10-30 nucleotides in length and flank a region about 50-200 nucleotides in length. Under appropriate conditions and with appropriate reagents, such primers are capable of amplifying a nucleic acid molecule that includes the nucleotide sequence flanked by the primer. PCR products can be detected by any suitable method, including but not limited to gel electrophoresis and staining with a DNA-specific stain or hybridization to a labeled probe.
[0101] In some cases, the presence of a polymorphism in a patient may be determined by analyzing the polypeptide product of a DED response marker (see Table 1). Detection of the polypeptide product can be performed using any method known in the art, including, but not limited to, immunocytochemical staining, ELISA, flow cytometry, Western blot, spectrometry, HPLC, and mass spectrometry.
[0102] One method of detecting polypeptide products in a sample is by using a probe that is a binding protein (e.g., an antibody) capable of specifically interacting with a marker protein. Preferably, a labeled antibody, binding portion thereof, or other binding partner can be used. The antibody can be of monoclonal or polyclonal origin, or may be biosynthetically produced. The binding partner can also be a naturally occurring molecule or synthetically produced. The amount of complexed protein is determined using standard protein detection methods described in the art. For a detailed review of immunological assay design, theory, and protocols, one can refer to numerous texts in the art, including Practical Immunology, Butt, WR, ed., Marcel Dekker, New York, 1984. A variety of assays are available for detecting proteins with labeled antibodies. Direct labels include fluorescent or luminescent tags, metals, dyes, radionucleides, etc., attached to the antibody. Indirect labels include various enzymes well known in the art, such as alkaline phosphatase, hydrogen peroxidase, etc. In a one-step assay, the polypeptide product, if present, is immobilized and incubated with a labeled antibody. The labeled antibody binds to the immobilized target molecule. After washing to remove unbound molecules, the sample is assayed for the label.
[0103] The use of immobilized antibodies specific for a protein or polypeptide is also contemplated by the present disclosure. Antibodies can be immobilized on a variety of solid supports, such as magnetic or chromatographic matrix particles, assay site surfaces (such as microtiter wells), or pieces of solid substrate material (such as plastic, nylon, paper, etc.). An assay strip can be prepared by coating an array of antibodies onto a solid support. The strip can then be dipped into a test sample and then quickly processed through washing and detection steps to generate a measurable signal, such as a colored spot.
[0104] In a two-step assay, the polypeptide product of the immobilized DED-responsive marker may be incubated with an unlabeled antibody. The unlabeled antibody complex, if present, then binds to a second labeled antibody specific for the unlabeled antibody. The sample is washed and assayed for the presence of the label. The choice of marker used to label the antibody will vary depending on the application. However, the choice of marker can be easily determined by one of skill in the art. The antibody may be labeled with a radioactive atom, an enzyme, a chromophore or fluorescent moiety, or a colorimetric tag. The choice of tagging label will also depend on the desired detection limit. Enzyme assays (ELISA) typically allow for the detection of a colored product formed by the interaction of an enzyme-tagged complex with an enzyme substrate. Some examples of radioactive atoms include: 32 P, 125 I, 3 H, and 14Some examples of enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, and glucose-6-phosphate dehydrogenase. Some examples of chromophore moieties include fluorescein and rhodamine. Antibodies may be conjugated to these labels by methods known in the art. For example, enzymes and chromophore molecules may be conjugated to antibodies using coupling agents such as dialdehydes, carbodiimides, dimaleimides, etc. Alternatively, conjugation may be performed by ligand-receptor pairs. Some suitable ligand-receptor pairs include, for example, biotin-avidin or -streptavidin, and antibody-antigen.
[0105] In one embodiment, the present disclosure contemplates the use of a sandwich technique for the detection of polypeptide products in biological samples. This technique requires two antibodies capable of binding to the protein of interest: for example, one immobilized on a solid support, and one free in solution but labeled with some easily detectable chemical compound. Examples of chemical labels that can be used for the secondary antibody include, but are not limited to, radioisotopes, fluorescent compounds, and enzymes or other molecules that generate colored or electrochemically active products upon exposure to a reactant or enzyme substrate. When a sample containing the polypeptide product is placed into the system, the polypeptide product binds to both the immobilized and labeled antibodies. The result is a "sandwich" immune complex on the support surface. Unbound sample components and excess labeled antibodies are washed away, and the complexed protein is detected by measuring the amount of labeled antibody complexed to the protein on the support surface. Sandwich immunoassays are highly specific and extremely sensitive, provided that a label with an appropriate detection limit is used.
[0106] Preferably, the presence of the polypeptide product in a sample is detected by radioimmunoassay or enzyme-linked immunoassay, competitive binding enzyme-linked immunoassay, dot blot, Western blot, chromatography, preferably high performance liquid chromatography (HPLC), or other assays known in the art. Specific immunological binding of an antibody to a protein or polypeptide can be detected directly or indirectly.
[0107] Dot blotting is routinely performed by those skilled in the art to detect a desired protein using an antibody as a probe (Promega Protocols and Applications Guide, Second Edition, 1991, Page 263, Promega Corporation). Using a dot blot apparatus, a sample is applied to a membrane. A labeled probe is incubated with the membrane and the presence of the protein is detected.
[0108] Western blot analysis is well known to those skilled in the art (Sambrook et al., Molecular Cloning, A Laboratory Manual, 1989, Vol. 3, Chapter 18, Cold Spring Harbor Laboratory). In a Western blot, samples are separated by SDS-PAGE. The gel is transferred to a membrane. The membrane is incubated with a labeled antibody to detect the desired protein.
[0109] The assays described above include, but are not limited to, steps such as immunoblotting, immunodiffusion, immunoelectrophoresis, or immunoprecipitation. In some embodiments, an automated analyzer is used to determine the presence of a DED response marker.
[0110] Disclosed herein is a method for predicting the likelihood that a patient having DED will respond to treatment with a TNFα antagonist, comprising detecting the presence or absence of a DED response marker in a biological sample from the patient, where: a) the presence of the DED response marker indicates an increased likelihood that the patient will respond to treatment with a TNFα antagonist; and b) the absence of the DED response marker indicates a decreased likelihood that the patient will respond to treatment with a TNFα antagonist.
[0111] In some embodiments, the method further comprises the step of obtaining a biological sample from a patient, where the obtaining step is performed prior to the assaying step.
[0112] In some embodiments, the DED response marker is detected by assaying the biological sample for a nucleic acid product of the DED response marker, a polypeptide product of the DED response marker, or an equivalent genetic marker of the DED response marker. In some embodiments, the DED response marker is detected by assaying the biological sample for a genomic sequence of the DED response marker. In some embodiments, the biological sample is selected from the group consisting of synovial fluid, blood, serum, feces, plasma, urine, tears, saliva, cerebrospinal fluid, a white blood cell sample, and a tissue sample.
[0113] In some embodiments, the presence of the DED responsive marker is detected by a technique selected from the group consisting of Northern blot analysis, polymerase chain reaction (PCR), reverse transcription polymerase chain reaction (RT-PCR), TaqMan-based assays, direct sequencing, dynamic allele-specific hybridization, high-density oligonucleotide SNP arrays, restriction fragment length polymorphism (RFLP) assays, primer extension assays, oligonucleotide ligase assays, single-stranded conformational polymorphism analysis, temperature gradient gel electrophoresis (TGGE), denaturing high performance liquid chromatography, high-resolution melting analysis, DNA mismatch binding protein assays, SNPLex®, capillary electrophoresis, Southern blot, immunoassays, immunohistochemistry, ELISA, flow cytometry, Western blot, HPLC, and mass spectrometry.
[0114] In some embodiments of the methods and uses of the present disclosure, the TNFα antagonist is a TNFα binding molecule or a TNFα receptor binding molecule. In some embodiments, the TNFα binding molecule or the TNFα receptor binding molecule is a TNFα binding molecule. In some embodiments, the TNFα binding molecule is a TNFα antibody or an antigen-binding portion thereof.
[0115] In some embodiments of the methods and uses of the present disclosure, the TNFα antibody is a recombinant humanized antibody. In some embodiments of the methods and uses of the present disclosure, the recombinant humanized TNFα antibody is LME636.
[0116] Methods of Treatment and Use of TNFα Antagonists The disclosed methods allow clinicians to provide individualized therapy to DED patients, i.e., the methods allow clinicians to determine whether to selectively treat patients with TNFα antagonists (e.g., LME636) or whether to selectively treat patients with over-the-counter treatments or topical cyclosporine. In this way, clinicians can maximize the benefits and minimize the risks of TNFα antagonism in the overall patient population suffering from DED. It will be appreciated that TNFα antagonists, such as TNFα binding molecules (e.g., TNFα antibodies or antigen-binding portions thereof, e.g., LME636) or TNFα receptor binding molecules (e.g., TNFα receptor antibodies or antigen-binding portions thereof), are useful in treating, preventing, or alleviating DED as disclosed herein (e.g., improving signs and symptoms and structural changes, ocular discomfort, etc.), particularly in patients with DED response markers.
[0117] TNFα antagonists, such as TNFα binding molecules (e.g., TNFα antibodies or antigen-binding portions thereof, e.g., LME636) or TNFα receptor binding molecules (e.g., TNFα receptor antibodies or antigen-binding portions thereof), may be used in vitro, ex vivo, or formulated into pharmaceutical compositions and administered in vivo to an individual (e.g., a human patient) to treat, alleviate, or prevent DED, for example, in a patient having a DED response marker. The pharmaceutical composition will be formulated to be compatible with its intended route of administration (e.g., oral compositions will generally include an inert diluent or an edible carrier). Other non-limiting examples of routes of administration include parenteral (e.g., intravenous), intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Pharmaceutical compositions compatible with each intended route are well known in the art.
[0118] A TNFα antagonist, such as a TNFα binding molecule (e.g., a TNFα antibody or antigen-binding portion thereof, e.g., LME636) or a TNFα receptor binding molecule (e.g., a TNFα receptor antibody or antigen-binding portion thereof), may be used as a pharmaceutical composition when combined with a pharma- ceutically acceptable carrier. Such compositions may contain, in addition to the TNFα antagonist, carriers, various diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The characteristics of the carrier will depend on the route of administration. The pharmaceutical compositions used in the methods of the present disclosure may also contain additional therapeutic agents for the treatment of a particular targeted disorder. For example, the pharmaceutical composition may also include other anti-inflammatory agents. Such additional factors and / or agents may be included in the pharmaceutical composition to produce a synergistic effect with the TNFα binding molecule, or to minimize side effects caused by a TNFα antagonist, such as a TNFα binding molecule (e.g., a TNFα antibody or antigen-binding portion thereof, e.g., LME636) or a TNFα receptor binding molecule (e.g., a TNFα receptor antibody or antigen-binding portion thereof).
[0119] The pharmaceutical compositions used in the disclosed methods may be prepared in conventional manner. In one embodiment, the pharmaceutical composition is provided in lyophilized form. For immediate administration, the pharmaceutical composition is dissolved in a suitable aqueous carrier, such as sterile water for injection or sterile buffered saline. If it is deemed desirable to make a large volume of solution for administration by infusion rather than bolus injection, it may be advantageous to incorporate human serum albumin or the patient's own heparinized blood into the saline at the time of formulation. The presence of such physiologically inactive proteins in excess prevents loss of antibody due to adsorption to the walls of containers and tubing used with the infusion solution. If albumin is used, the preferred concentration is 0.5-4.5% by weight of the saline. Other formulations include liquid or lyophilized formulations.
[0120] Antibodies, such as antibodies against TNFα, are typically formulated either in aqueous form for immediate parenteral administration or as lyophilizates that are reconstituted with a suitable diluent prior to administration. In some embodiments of the methods and uses of the present disclosure, TNFα antagonists, such as TNFα antibodies, such as LME636, are formulated as lyophilizates. Suitable lyophilized formulations can be reconstituted in small liquid volumes (e.g., 2 ml or less) to allow for subcutaneous administration and provide solutions with low levels of antibody aggregation.
[0121] The appropriate dosage will, of course, vary depending on, for example, the particular TNFα antagonist utilized, such as a TNFα binding molecule (e.g., a TNFα antibody or antigen-binding portion thereof, e.g., LME636) or a TNFα receptor binding molecule (e.g., a TNFα receptor antibody or antigen-binding portion thereof), the host, the mode of administration, and the nature and severity of the condition being treated, and on the nature of prior treatments the patient has undergone. Ultimately, the amount of TNFα antagonist with which to treat each individual patient will be determined by the attending healthcare provider. In some embodiments, the attending healthcare provider may administer a low dose of a TNFα antagonist and observe the patient's response. In other embodiments, the initial dose or doses of TNFα antagonist administered to the patient are high and then tapered until signs of relapse appear. Higher doses of TNFα antagonist may be administered, where once an optimal therapeutic effect for the patient is achieved, the dosage is generally not further increased.
[0122] In some implementations of the therapeutic methods or uses of the present disclosure, a therapeutically effective amount of a TNFα antagonist, such as a TNFα binding molecule (e.g., a TNFα antibody or antigen-binding portion thereof, e.g., LME636) or a TNFα receptor binding molecule (e.g., a TNFα antibody or antigen-binding portion thereof) is administered to a patient, e.g., a mammal (e.g., a human). It is understood that the methods of the present disclosure provide for selective treatment of a patient (i.e., a patient with DED) depending on the presence of a DED response marker, but this does not exclude that if the patient is ultimately treated with a TNFα antagonist, such TNFα antagonist therapy will necessarily be a monotherapy. Indeed, if a patient is selected for treatment with a TNFα antagonist, the methods of the present disclosure may either administer a TNFα antagonist (e.g., LME636) alone or in combination with other therapeutic agents for the treatment of the patient's DED. When co-administered with one or more additional therapeutic agents, the TNFα antagonist may be administered simultaneously or sequentially with the other therapeutic agents. If administered sequentially, the appropriate sequence of administration of the TNFα antagonist in combination with other therapeutic agents, as well as appropriate dosages for co-delivery, will be determined by the attending physician.
[0123] TNFα antagonists can be conveniently administered parenterally, intravenously, for example, into the antecubital vein or other peripheral vein, intramuscularly, or subcutaneously. The duration of intravenous (iv) therapy using the pharmaceutical composition of the present disclosure will vary depending on the severity of the disease being treated and the condition and personal response of each individual patient. Subcutaneous (sc) therapy using the pharmaceutical composition of the present disclosure is also contemplated. The appropriate duration of iv or sc therapy using the pharmaceutical composition of the present disclosure and the timing of administration of the therapy will be determined by the medical provider.
[0124] In certain embodiments, the TNFα antagonist, e.g., LME636, can be delivered directly to the eye by ocular tissue injection, such as periorbital, conjunctival, subtenon, intracameral, intravitreal, intraocular, subretinal, subconjunctival, retrobulbar, or intracanalicular injection; by direct application to the eye using a catheter or other placement device, such as a retinal pellet, intraocular insert, suppository, or implant, comprising a porous, non-porous, or gelatinous material; by topical eye drops or ointments; or by a sustained release device implanted in the conjunctival sac or adjacent to the sclera (transscleral) or on the sclera (intrascleral) or within the eye. Intracanalicular injection may be into the venous collecting duct draining Schlemm's canal, or into Schlemm's canal.
[0125] For ocular delivery, the antibodies of the invention may be combined with ophthalmologically acceptable preservatives, co-solvents, surfactants, viscosity enhancers, penetration enhancers, buffers, sodium chloride, or water to form an aqueous sterile ophthalmic suspension or solution. Topical ophthalmic formulations may be packaged, for example, in multi-dose form. Preservatives may therefore be necessary to prevent microbial contamination during use. Suitable preservatives include chlorobutanol, methylparaben, propylparaben, phenylethyl alcohol, edetate disodium, sorbic acid, polyquaternium-1, or other agents known to those skilled in the art. Such preservatives are typically utilized at levels of 0.001-1.0% w / v. The unit dose compositions of the invention may be sterile, but are typically not preserved. Thus, such compositions generally do not contain preservatives.
[0126] In certain embodiments, compositions intended for topical administration to the eye are formulated as eye drops or eye ointments, in which the total amount of antibody can be about 0.1-10.0% (w / w).Preferably, the amount of TNFα antagonist, e.g., LME636, is about 5.0-10.0% (w / w), most preferably about 6.0% (w / w).
[0127] The compositions of the present invention in certain circumstances will be administered as a topical solution. Aqueous solutions are generally preferred due to ease of formulation and the ease with which the patient can administer such compositions by placing one or two drops of the solution on the affected eye. However, the compositions may also be suspensions, viscous or semi-viscous gels, or other types of solid or semi-solid compositions.
[0128] The therapeutically effective amount of antibody present in the formulation is determined, for example, by considering the desired dose volume and one or more modes of administration. Exemplary antibody concentrations in the formulation are from about 1.0 mg / ml to about 100 mg / ml, preferably from about 5.0 mg / ml to about 80 mg / ml, and most preferably from about 10.0 mg / ml to about 60 mg / ml.
[0129] As a general proposition for systemic administration, the therapeutically effective amount of TNFα antagonist, e.g., LME636, administered may range from about 0.1 to about 100 mg / kg of patient body weight, whether in one or more doses, with typical ranges of antibodies used being, for example, about 0.3 to about 20 mg / kg, more preferably about 0.3 to about 15 mg / kg, administered daily. However, other dosage regimes may be useful. The progress of this therapy is easily monitored by conventional techniques.
[0130] Disclosed herein is a method of selectively treating a patient with DED comprising either a) selectively administering a therapeutically effective amount of a TNFα antagonist to the patient based on the patient having a DED response marker, where the DED response marker is the rs1800693 response allele.
[0131] In some embodiments, the method further comprises the step of obtaining a biological sample from a patient, where the obtaining step is performed prior to the assaying step.
[0132] In some embodiments of the methods and uses of the disclosure, the DED response marker is detected by assaying a biological sample for a nucleic acid product of the DED response marker, a polypeptide product of the DED response marker, or an equivalent genetic marker of the DED response marker.
[0133] In some embodiments of the methods and uses of the present disclosure, the DED response marker is detected by assaying a biological sample for a genomic sequence of the DED response marker.
[0134] In some embodiments of the methods and uses of the present disclosure, the biological sample is selected from the group consisting of synovial fluid, blood, serum, stool, plasma, urine, tears, saliva, cerebrospinal fluid, a white blood cell sample, and a tissue sample.
[0135] In some embodiments of the methods and uses of the present disclosure, the DED response marker is detected by a technique selected from the group consisting of Northern blot analysis, polymerase chain reaction (PCR), reverse transcription polymerase chain reaction (RT-PCR), TaqMan-based assay, direct sequencing, dynamic allele-specific hybridization, high-density oligonucleotide SNP array, restriction fragment length polymorphism (RFLP) assay, primer extension assay, oligonucleotide ligase assay, single-stranded conformational polymorphism analysis, temperature gradient gel electrophoresis (TGGE), denaturing high performance liquid chromatography, high-resolution melting analysis, DNA mismatch binding protein assay, SNPLex®, capillary electrophoresis, Southern blot, immunoassay, immunohistochemistry, ELISA, flow cytometry, Western blot, HPLC, and mass spectrometry.
[0136] kit The present invention also encompasses kits for detecting DED response markers in a biological sample (test sample) from a patient. Such kits can be used to predict whether a patient with DED is likely to respond (or have a higher response) to treatment with a TNFα antagonist, such as a TNFα binding molecule (e.g., a TNFα antibody or an antigen-binding portion thereof, e.g., LME636) or a TNFα receptor binding molecule (e.g., a TNFα antibody or an antigen-binding portion thereof). For example, the kit can include a probe (e.g., an oligonucleotide, an antibody, a labeled compound, or other agent) capable of detecting the DED response markers, their allelic products, and / or their allelic equivalent genetic markers in a biological sample. The kit can also include instructions for providing a prediction of the likelihood that a patient will respond to treatment with a TNFα antagonist.
[0137] The probe may specifically hybridize to a genomic sequence, a nucleic acid product, or a polypeptide product. Exemplary probes are oligonucleotides or conjugated oligonucleotides that specifically hybridize to the response alleles of Table 1 (e.g., from DNA, cDNA, mRNA, etc.); primer extension oligonucleotides, allele-specific primers, combinations of allele-specific primers, allele-specific probes, and primer extension primers, etc. Optionally, the kit may include a probe that targets an internal standard allele, which may be any allele that is present in the general population. Detection of the internal standard allele is designed to ensure the performance of the kit. The kit of the present disclosure may also include, for example, a buffer, a preservative, or a protein stabilizer. The kit may also include components (e.g., enzymes or substrates) necessary for detection of the detectable agent. The kit may also include a control sample or a series of control samples that can be assayed and compared to the included test sample. Each component of the kit is usually enclosed in an individual container, and all of the various containers are in a single package along with instructions for use.
[0138] Such kits may also include a pharmaceutical composition comprising a TNFα antagonist, such as a TNFα binding molecule (e.g., a TNFα antibody or antigen-binding portion thereof, e.g., LME636) or a TNFα receptor binding molecule (e.g., a TNFα antibody or antigen-binding portion thereof) (e.g., in liquid or lyophilized form) or a TNFα antagonist (described above). As such, such kits are useful for selectively treating DED with a TNFα antagonist (e.g., LME636). In addition, such kits may include means for administration of the TNFα antagonist (e.g., syringes and vials, pre-filled syringes, pre-filled pens) and instructions for use. These kits may also include additional therapeutic agents (described above) for treating DED, for example delivered in combination with the enclosed TNFα antagonist, e.g., LME636.
[0139] The phrase "administration means" is used to refer to any available implementation for systemically administering a drug to a patient, including, but not limited to, pre-filled syringes, vials and syringes, injection pens, auto-injectors, intravenous drips and bags, pumps, etc. Such items may be used by a patient to self-administer a drug (i.e., administer the drug to themselves) or by a physician to administer the drug.
[0140] overview The above attached description provides details of one or more embodiments of the present disclosure. Although any methods and materials similar or equivalent to those described herein may be used in the practice or testing of the present disclosure, the preferred methods and materials are described herein. Other features, objects, and advantages of the present disclosure will become apparent from this description and the claims. In this specification and the appended claims, the singular forms include plural referents unless the context clearly dictates otherwise. Unless otherwise defined, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosure belongs. All patents and publications cited herein are incorporated by reference. The following examples are provided to more fully illustrate the preferred embodiments of the present disclosure. These examples should in no way be construed as limiting the scope of the disclosed patient subject matter as defined by the appended claims. EXAMPLES
[0141] Example 1 - CLME636X2202A Study: LME636 Improves Signs and Symptoms of Dry Eye Disease CLME636X2202A was a proof-of-concept (PoC) study to determine the efficacy and safety of topical ocular treatment with LME636 in patients with severe dry eye disease (DED). The primary objective of this PoC study was to demonstrate the efficacy of topically administered LME636 compared to LME636 vehicle in reducing ocular symptoms as determined by global ocular discomfort score on day 29 of treatment. A key secondary objective was to determine the percentage of patients with an improvement in global ocular discomfort score >20 (responder analysis). DNA samples were collected from patients who provided written informed consent and preliminary pharmacogenetic analysis was performed to identify genetic factors that may influence response to LME636 treatment. Pharmacogenetic analysis is described in Example 2.
[0142] During the treatment phase, 69 patients were randomized to receive LME636 and 65 to receive LME636 vehicle. 67 and 64 patients in LME636 and LME636 vehicle, respectively, completed the study and were part of the per-protocol analysis. Demographic and baseline characteristics were well balanced between the two groups (LME636 vs. LME636 vehicle), including the following parameters: mean age 61.7 vs. 58.8 years; 61 vs. 54 female patients; mean overall ocular discomfort at baseline 77.9 vs. 80.3.
[0143] For the primary efficacy endpoint, changes from baseline in global ocular discomfort scores (LME636 vs LME636 vehicle): -7.9 [1.45 SE] vs -3.6 [1.49 SE] at day 29 (primary timepoints and per-protocol analysis set) and -10.5 [1.74 SE] vs -5.4 [1.77 SE] at day 43 (exploratory timepoints from the full analysis set). The 90% confidence interval for the difference in changes from baseline at day 29 was -7.7 to -0.8.
[0144] For LME636 vs. LME636 vehicle, the number of patients who achieved an improvement from baseline in general ocular discomfort of ≥20 units at Day 29 was 12 (17.9%) vs. 3 (4.7%) with a p-value based on chi-square test and Wald interval of 0.018 (responder analysis).
[0145] In conclusion, these results met the prespecified criteria for the primary analysis and were further supported by the responder analysis: improvements were sustained from days 29 to 43.
[0146] Example 2: Materials and methods for pharmacogenetic (PG) analysis Example 2.1: Samples and treatments A total of 127 patient samples were collected. Patients who met all of the following criteria were included in the pharmacogenetic analysis: Provided written informed consent to the pharmacogenetic study. -DNA extraction and genotyping were successful. -Included in the overall analysis of the clinical trial.
[0147] Blood samples were collected from consenting patients at a separate testing facility and then shipped to Pharmaceutical Product Development (Wilmington, NC 28401). Genomic DNA from each patient was extracted from blood by Covance (Indianapolis, IN 46214), and genotyping data were generated using TaqMan technology by Clinical Reference Laboratory (Lenexa, KS 66215). Of the nine SNPs, eight were successfully genotyped, and one (rs115575857) did not genotype due to local DNA sequence complexity. For these eight SNPs, 126 of 127 DNA samples were successfully genotyped. One patient sample had questionable DNA quality and failed genotyping. Two duplicate samples were included as quality controls.
[0148] Several candidate genes and single nucleotide polymorphisms (SNPs) were selected for PG analysis based on being in the drug target (TNF-α) or its receptor (TNFR1) or being genetic variants highly associated with Sjögren's syndrome (see Table 1).
[0149] [Table 3]
[0150] Example 2.2: Statistical Analysis Primary Efficacy Endpoint The primary efficacy endpoint was the change from baseline in global ocular discomfort score to day 29. Efficacy analyses were performed using a per-protocol set.
[0151] To test for genotype effect in patients treated with LME636, a mixed-model repeated measures analysis was performed with terms for baseline global discomfort score, genotype, number of days on treatment, genotype × number of days on treatment interaction, age, and race. Estimates of the difference in mean change from baseline in global discomfort between genotype groups and associated 90% confidence intervals are presented.
[0152] To test for interaction between genotype and treatment on day 29 of treatment, an ANCOVA model was used, including baseline global discomfort score, age, and race as covariates. Estimates of the difference in mean change from baseline in global discomfort between genotype groups and associated 90% confidence intervals are presented.
[0153] All statistical tests were two-sided. Bonferroni correction was applied to adjust for multiple testing. For any genetic effect that achieved p≦0.1 after adjustment for multiple testing, scatter or waterfall plots displaying individual patient data will be presented.
[0154] Ranked Secondary Efficacy Endpoints The key secondary efficacy endpoint was the percentage of patients (defined as responders) with an improvement in global ocular discomfort score >20 from baseline to day 29 of treatment. Efficacy analyses used a per-protocol set.
[0155] Fisher's exact test was used. Only genotypes associated with the primary endpoint were analyzed. The percentage of patients with improvement in global ocular discomfort score >20 between genotype groups is presented.
[0156] Example 3: PG analysis results Example 3.1: Comparison of PG and total study population A total of 126 patient samples were successfully genotyped for the eight SNPs. Two duplicates introduced for quality control showed 100% concordance for the eight SNP genotypes. Of the 126 patients with genotype data, 88 entered treatment. Of those 88 patients with genotype data and who entered treatment, 86 were in the per-protocol analysis set. In contrast, the full study had 131 patients in the per-protocol analysis set. Table 3 summarizes the demographic characteristics, baseline general ocular discomfort scores, and response rates to treatment in the PG population and the full study, respectively. The PG population appeared similar to the full study as determined by these variables, particularly the baseline general ocular discomfort scores.
[0157] [Table 4]
[0158] Example 3.2: Primary Efficacy Endpoint Analysis - Initial Association Test As in the comprehensive clinical trial, mixed-model repeated-measures analysis was used to test for association between genotype and change from baseline in global ocular discomfort score at day 29 of treatment. Of the eight SNPs tested, only rs1800693 showed a significant effect after Bonferroni correction on response to LME636 (p<0.0001) (Table 4). SNP rs1800629 showed a nominally significant association with the clinical endpoint (p=0.0159), but this significance disappeared after Bonferroni correction (p=0.1272).
[0159] [Table 5]
[0160] As shown in Table 5, the genotype effect of rs1800693 on symptom improvement was only seen in patients treated with LME636, but not in those treated with vehicle. Patients with the CC genotype tended to have greater improvement than patients with the CT or TT genotypes.
[0161] [Table 6]
[0162] Example 3.3: Primary Efficacy Endpoint Analysis - Interaction between Treatment and Genotype Next, we tested whether there was an interaction between treatment and genotype using an analysis of covariance (ANCOVA) model. Similar to the initial mixed model analysis, only rs1800693 showed a significant interaction on day 29 of treatment (p=0.0076) (Table 6). The interaction remained significant after Bonferroni correction (p=0.0608).
[0163] [Table 7]
[0164] [Table 8]
[0165] The interaction test was only for day 29 of treatment. However, there were missing values for individual treatment days. To improve understanding of the interaction between treatment and rs1800693, we further tested the interaction from day 23 to day 28. As shown in Table 7, a similar trend of interaction was observed from day 23 to day 29.
[0166] [Table 9]
[0167] [Table 10]
[0168] Example 3.4: Key Secondary Efficacy Endpoint Analyses The secondary efficacy endpoint analysis focused on the response rate between genotype groups. Only rs1800693 was analyzed because it was the only SNP associated with the primary efficacy endpoint. As shown by Fisher's exact test, the response rate was much higher in patients with the CC genotype compared with patients with the CT or TT genotype (Table 8). These results support the primary efficacy endpoint analysis. However, due to the small number of responders, caution is advised in interpretation.
[0169] [Table 11]
[0170] [Table 12]
[0171] Example 3.5: Visualization of individual patient data This pharmacogenetic analysis included 12 CC genotype patients. To visualize and compare symptomatic changes between treatments, the change from baseline in the overall ocular discomfort score for these 12 CC genotype patients was plotted against treatment days from baseline to day 43. As shown in Figure 1, three of four patients treated with LME636 had significant symptomatic improvement over time. In contrast, among the eight vehicle-treated patients, none consistently showed symptomatic improvement greater than 10 units. The difference in symptomatic improvement between LME636 and vehicle at day 29 of treatment was significant by ANCOVA analysis (p<0.0001).
[0172] The change from baseline in overall ocular discomfort scores for all patients was further illustrated by waterfall plots, allowing visualization of symptomatic change by treatment and genotype (Figures 2-5). Interestingly, only minimal media responses were seen in patients with the CC genotype, while media responses of >10 occurred within the CT and TT groups. This data suggests that patients with the CC genotype may simply have a form of dry eye disease that is unlikely to be relieved by media.
[0173] conclusion In this preliminary pharmacogenetic analysis, we used a candidate gene approach and focused on genes related to the mechanism of action of LME636 and genes associated with Sjögren's syndrome. Due to the small sample size, only eight SNPs were included in the analysis to reduce the burden of adjustment for multiple testing. Three SNPs in the TNF-α gene were reported to be associated with response to anti-TNF agents in patients with autoimmune diseases such as rheumatoid arthritis (Julia A, Fernandez-Nebro A, Blanco F, Ortiz A, Canyete JD, et al. (2016). A genome-wide association study identifies a new locus associated with the response to anti-TNF therapy in rheumatoid arthritis. Pharmacogenomics J. 16(2): 147-50). One SNP in the TNFR1 gene, primarily associated with multiple sclerosis (MS), causes skipping of exon 6, resulting in the production of soluble TNFR1 (sTNFR1) (De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, et al. (2009). Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet. 41(7):776-82; Gregory AP, Dendrou CA, Attfield KE, Haghikia A, Xifara DK, et al. (2012). TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature. 23; 488(7412):508-11).To examine the potential impact of Sjoegren's syndrome risk alleles on response to LME636 in DED patients, four SNPs strongly associated with Sjoegren's syndrome were included in this analysis (Lessard CJ, Li H, Adrianto I, Ice JA, Rasmussen A, Grundahl KM, et al. (2013). Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjoegren's syndrome. Nat Genet. 45(11):1284-92).
[0174] sTNFR1 is constitutively released from the cell membrane by TNF-alpha-converting enzyme, and its levels increase during the course of various human diseases, including Sjögren's syndrome, uveitis, and glaucoma. (Touchard E, Bloquel C, Bigey P, Kowalczuk L, Jonet L, et al. (2009). Local ocular immunomodulation resulting from electrotransfer of plasmid encoding soluble TNF receptors in the ciliary muscle. Gene Ther. 16(7):862-73; Sakimoto T, Yamada A, Sawa M. (2009). Release of soluble tumor necrosis factor receptor 1 from corneal epithelium by TNF-alpha-converting enzyme-dependent ectodomain shedding. Invest Ophthalmol Vis Sci. 50(10):4618-21; Sakimoto T, Ohnishi T, Ishimori A. (2014). Significance of ectodomain shedding of TNF receptor 1 in ocular surface.Invest Ophthalmol Vis Sci.55(4):2419-23). In contrast, mutations impairing the sTNFR1 production process cause the autoinflammatory disorder periodic syndrome (Magnotti F, Vitale A, Rigante D, Lucherini OM, Cimaz R, et al.(2013).The most recent advances in pathophysiology and management of tumour necrosis factor receptor-associated periodic syndrome(TRAPS):personal experience and literature review.Clin Exp Rheumatol.31(3 Suppl 77):141-9).Thus, an imbalance in sTNFR1 production may contribute to the pathogenesis of human diseases. Some mechanistic studies have suggested that sTNFR1 may act as a physiological attenuator of TNF-α activity or function as a buffer system to enhance the effect of TNF-α (Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. (1992). Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 175(2): 323-9; Gregory AP, Dendrou CA, Attfield KE, Haghikia A, Xifara DK, et al. (2012). TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature. 23; 488(7412): 508-11). rs1800693 is considered a novel mechanism of sTNFR1 production. A recent study demonstrated that the rs1800693 CC genotype correlated with increased signaling to TNF-α and that this change in signaling could be due to altered localization of sTNFR1 within the cell (Housley WJ, Fernandez SD, Vera K, Murikinati SR, Grutzendler J, et al. (2015). Genetic variants associated with autoimmunity drive NFκB signaling and responses to inflammatory stimuli. Sci Transl Med. 10; 7(291): 291ra93).
[0175] As reported in the 1000 Human Genomes Database, the prevalence of CC is 19.9% and 12.7% in Caucasians and Africans, respectively. In contrast (in contract), the prevalence of CC is 11.5% (11 / 96) and 12.7% (2 / 19) in Caucasians and Africans, respectively, in the LME636X2202 study. No genome-wide genetic association studies for dry eye disease have been reported in the literature. It is unknown whether rs1800693 has an effect on dry eye disease risk.
[0176] The inventors have identified certain genetic variations that are predictive of response to TNFα antagonism, such as TNFα antibodies, e.g., LME636, in particular in DED. The findings disclosed herein would not have been predicted based solely on the fact that certain SNPs may be associated with an increased likelihood of a patient developing DED. The findings disclosed herein would not have been predicted based solely on the particular gene in which the SNP was studied. Indeed, of the eight SNPs tested, four were known to be associated with the TNFα pathway and four were known to be associated with Sjögren's syndrome, but only rs1800693, located in the TNFR1 gene, showed a significant effect on response to LME636 treatment. Patients with CC genotypes tended to have much greater improvement in terms of symptoms than patients with CT or TT genotypes. Therefore, how well a patient will respond to a drug cannot be predicted solely on the basis of whether the patient carries an allele associated with a particular disease state or whether the patient carries a SNP in a particular gene.
[0177] The inventors conclude that the predictive methods and personalized therapy disclosed herein are useful for maximizing the benefits and minimizing the risks of TNFα antagonism in patients with DED by identifying patients who are likely to respond prior to treatment with TNFα antagonists such as LME636. The present invention also provides the following. [1] A method for selectively treating a patient having dry eye disease (DED), comprising selectively administering a therapeutically effective amount of a TNFα antagonist to the patient based on the patient having a DED response marker, wherein the DED response marker is an rs1800693 response allele. [2] 1. A method of selectively treating a patient with dry eye disease (DED) with a TNFα antagonist, comprising: a) selecting the patient for treatment with the TNFα antagonist based on the patient having a DED response marker; and b) then administering to said patient a therapeutically effective amount of said TNFα antagonist. Includes; The method, wherein the DED response marker is the rs1800693 response allele. [3] 1. A method of selectively treating a patient with dry eye disease (DED) with a TNFα antagonist, comprising: a) assaying a biological sample from said patient for a DED response marker; and b) then selectively administering to said patient a therapeutically effective amount of a TNFα antagonist based on said biological sample from said patient having said DED response marker. Includes; The method, wherein the DED response marker is the rs1800693 response allele. [4] 1. A method of selectively treating a patient with dry eye disease (DED) with a TNFα antagonist, comprising: a) assaying a biological sample from said patient for a DED response marker; b) then selecting the patient for treatment with the TNFα antagonist based on the biological sample from the patient having the DED response marker; and c) then administering to said patient a therapeutically effective amount of said TNFα antagonist. Includes; The method, wherein the DED response marker is the rs1800693 response allele. [5] The method of [3] or [4], wherein the assaying step comprises assaying the biological sample for a nucleic acid product of the DED response marker, a polypeptide product of the DED response marker, or an equivalent genetic marker of the DED response marker. [6] The method of claim 5, wherein the assaying step comprises assaying the biological sample for a genomic sequence of the DED response marker. [7] The method according to any one of [3] to [6], wherein the biological sample is selected from the group consisting of synovial fluid, blood, serum, feces, plasma, urine, tears, saliva, cerebrospinal fluid, a leukocyte sample, and a tissue sample. [8] The method according to any one of [3] to [7], wherein the assaying step comprises a technique selected from the group consisting of Northern blot analysis, polymerase chain reaction (PCR), reverse transcription polymerase chain reaction (RT-PCR), TaqMan-based assay, direct sequencing, dynamic allele-specific hybridization, high-density oligonucleotide SNP array, restriction fragment length polymorphism (RFLP) assay, primer extension assay, oligonucleotide ligase assay, single-stranded conformational polymorphism analysis, temperature gradient gel electrophoresis (TGGE), denaturing high performance liquid chromatography, high-resolution melting analysis, DNA mismatch binding protein assay, SNPLex (registered trademark), capillary electrophoresis, Southern blot, immunoassay, immunohistochemistry, ELISA, flow cytometry, Western blot, HPLC, and mass spectrometry. [9] A TNFα antagonist for use in treating a patient having dry eye disease (DED), wherein a therapeutically effective amount of the TNFα antagonist is administered to the patient on the basis that the patient has a DED response marker, the DED response marker being an rs1800693 response allele.
[10] A TNFα antagonist for use in treating patients with dry eye disease (DED), a) the patient is selected for treatment with the TNFα antagonist based on the patient having a DED response marker; and b) a therapeutically effective amount of said TNFα antagonist is then administered to said patient; A TNFα antagonist, characterized in that the DED response marker is the rs1800693 response allele.
[11] A TNFα antagonist for use in treating patients with dry eye disease (DED), a) a biological sample from the patient is assayed for a DED response marker; and b) selectively administering to the patient a therapeutically effective amount of the TNFα antagonist based on the biological sample from the patient having the DED response marker; A TNFα antagonist, characterized in that the DED response marker is the rs1800693 response allele.
[12] A TNFα antagonist for use in treating patients with dry eye disease (DED), a) a biological sample from said patient is assayed for a DED response marker; b) the patient is selected for treatment with the TNFα antagonist based on the biological sample from the patient having the DED response marker; and c) a therapeutically effective amount of said TNFα antagonist is selectively administered to said patient; A TNFα antagonist, characterized in that the DED response marker is the rs1800693 response allele.
[13] A method for predicting the likelihood that a patient having dry eye disease (DED) will respond to treatment with a TNFα antagonist, comprising assaying a biological sample from the patient for the presence or absence of a DED response marker, the presence of the DED response marker indicating an increased likelihood that the patient will respond to treatment with the TNFα antagonist, and the DED response marker is an rs1800693 response allele.
[14] The method of claim 13, further comprising the step of obtaining the biological sample from the patient, the obtaining step being performed prior to the detecting step.
[15] The method of any one of
[11] to
[13] , wherein the assaying step comprises assaying the biological sample for a nucleic acid product of the DED response marker, a polypeptide product of the DED response marker, or an equivalent genetic marker of the DED response marker.
[16] The method of claim 15, wherein the assaying step comprises assaying the biological sample for a genomic sequence of the DED response marker.
[17] The method according to any one of
[11] to
[16] , wherein the biological sample is selected from the group consisting of synovial fluid, blood, serum, feces, plasma, urine, tears, saliva, cerebrospinal fluid, a leukocyte sample, and a tissue sample.
[18] The method according to any one of
[11] to
[17] , wherein the assaying step comprises a technique selected from the group consisting of Northern blot analysis, polymerase chain reaction (PCR), reverse transcription polymerase chain reaction (RT-PCR), TaqMan-based assay, direct sequencing, dynamic allele-specific hybridization, high-density oligonucleotide SNP array, restriction fragment length polymorphism (RFLP) assay, primer extension assay, oligonucleotide ligase assay, single-stranded conformation polymorphism analysis, temperature gradient gel electrophoresis (TGGE), denaturing high performance liquid chromatography, high-resolution melting analysis, DNA mismatch binding protein assay, SNPLex (registered trademark), capillary electrophoresis, Southern blot, immunoassay, immunohistochemistry, ELISA, flow cytometry, Western blot, HPLC, and mass spectrometry.
[19] 1. A method for producing information in a transferable form for predicting responsiveness of a patient having dry eye disease (DED) to treatment with a TNFα antagonist, comprising: a) determining an increased likelihood that the patient will respond to treatment with the TNFα antagonist based on the presence of a DED response marker in a biological sample from the patient, wherein the DED response marker is an rs1800693 response allele; and b) recording the results of said determining step in a tangible or intangible form for use in communication; The method includes:
[20] The method or use according to any one of [1] to
[19] , wherein the DED is moderate to severe.
[21] The method or use according to any one of [1] to
[20] , wherein the DED response marker is rs1800693 C / C allele.
[22] The method or use according to any one of [1] to
[21] , wherein the TNFα antagonist is a TNFα-binding molecule or a TNFα receptor-binding molecule.
[23] The method or use according to
[22] , wherein the TNFα antagonist is a TNFα binding molecule.
[24] The method or use according to
[23] , wherein the TNFα binding molecule is a TNFα antibody or an antigen-binding portion thereof.
[25] a) a heavy chain variable domain (V) comprising the amino acid sequence shown as SEQ ID NO: 8 H ); b) a light chain variable domain (V) comprising the amino acid sequence shown as SEQ ID NO: 7 L ); c) V comprising the amino acid sequence shown as SEQ ID NO:8 H V domain and the amino acid sequence shown as SEQ ID NO:7 L domain; d) V comprising the hypervariable regions shown as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 H domain; e) V comprising hypervariable regions as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6 L domain; f) V comprising the hypervariable regions shown in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 H V domain and hypervariable regions shown as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6 L Domain; and g) SEQ ID NO: 9 The method or use according to
[24] , wherein the TNFα antibody comprises
[26] The method or use according to
[25] , wherein the TNFα antibody is a recombinant antibody.
[27] The method or use according to
[26] , wherein the TNFα antibody is LME636.
[0178] Sequence Listing [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka]
change
change
Claims
1. A composition for treating a patient having dry eye disease (DED), comprising an anti-TNFα antibody or an antigen-binding portion thereof, wherein the patient has a DED response marker, the DED response marker being the rs1800693 C / C allele, and the anti-TNFα antibody or antigen-binding portion thereof is a) a VH domain comprising the amino acid sequence set forth as SEQ ID NO:8, and a VL domain comprising the amino acid sequence set forth as SEQ ID NO:7; b) a VH domain comprising hypervariable regions as set forth in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and a VL domain comprising hypervariable regions as set forth in SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6; or c) the sequence of SEQ ID NO: 9 A composition comprising:
2. A composition for treating a patient having dry eye disease (DED), comprising an anti-TNFα antibody or an antigen-binding portion thereof, a) the patient is selected for treatment with the anti-TNFα antibody, or antigen-binding portion thereof, based on the patient having a DED response marker; and b) then administering to the patient a therapeutically effective amount of said TNFα antagonist; the DED response marker is rs1800693 C / C allele, and the anti-TNFα antibody, or antigen-binding portion thereof, a) a VH domain comprising the amino acid sequence set forth as SEQ ID NO:8, and a VL domain comprising the amino acid sequence set forth as SEQ ID NO:7; b) a VH domain comprising hypervariable regions as set forth in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and a VL domain comprising hypervariable regions as set forth in SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6; or c) the sequence of SEQ ID NO: 9 A composition comprising:
3. A composition for treating a patient having dry eye disease (DED), comprising an anti-TNFα antibody or an antigen-binding portion thereof, a biological sample from the patient having a DED response marker; the DED response marker is the rs1800693 C / C allele; the anti-TNFα antibody, or antigen-binding portion thereof, a) a VH domain comprising the amino acid sequence set forth as SEQ ID NO:8, and a VL domain comprising the amino acid sequence set forth as SEQ ID NO:7; b) a VH domain comprising hypervariable regions as set forth in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and a VL domain comprising hypervariable regions as set forth in SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6; or c) the sequence of SEQ ID NO: 9 A composition comprising:
4. A composition for treating a patient having dry eye disease (DED), comprising an anti-TNFα antibody or an antigen-binding portion thereof, a) a biological sample from said patient is assayed for a DED response marker; b) selecting the patient for treatment with the anti-TNFα antibody, or antigen-binding portion thereof, based on the biological sample from the patient having the DED response marker; and c) selectively administering to said patient a therapeutically effective amount of said anti-TNFα antibody, or an antigen-binding portion thereof; the DED response marker is the rs1800693 C / C allele; the anti-TNFα antibody, or antigen-binding portion thereof, a) a VH domain comprising the amino acid sequence set forth as SEQ ID NO:8, and a VL domain comprising the amino acid sequence set forth as SEQ ID NO:7; b) a VH domain comprising hypervariable regions as set forth in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and a VL domain comprising hypervariable regions as set forth in SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6; or c) the sequence of SEQ ID NO: 9 A composition comprising:
5. The composition of claim 4 , wherein the assay comprises assaying the biological sample for a nucleic acid product of the DED response marker, a polypeptide product of the DED response marker, or an equivalent genetic marker of the DED response marker.
6. The composition of claim 5 , wherein the assay comprises assaying the biological sample for a genomic sequence of the DED response marker.
7. 7. The composition of any one of claims 4 to 6, wherein the assay comprises a technique selected from the group consisting of Northern blot analysis, polymerase chain reaction (PCR), reverse transcription polymerase chain reaction (RT-PCR), TaqMan-based assays, direct sequencing, dynamic allele-specific hybridization, high-density oligonucleotide SNP arrays, restriction fragment length polymorphism (RFLP) assays, primer extension assays, oligonucleotide ligase assays, single-stranded conformational polymorphism analysis, temperature gradient gel electrophoresis (TGGE), denaturing high performance liquid chromatography, high-resolution melting analysis, DNA mismatch binding protein assays, SNPLex®, capillary electrophoresis, Southern blot, immunoassays, immunohistochemistry, ELISA, flow cytometry, Western blot, HPLC, and mass spectrometry.
8. The composition of any one of claims 3 to 7, wherein the biological sample is selected from the group consisting of synovial fluid, blood, serum, faeces, plasma, urine, tears, saliva, cerebrospinal fluid, a white blood cell sample and a tissue sample.
9. The composition of any one of claims 1 to 8, wherein the DED is moderate to severe.
10. The composition of any one of claims 1 to 9, wherein the anti-TNFα antibody is a recombinant antibody.
11. The composition of claim 10, wherein the anti-TNFα antibody is LME636.
12. 1. A method of predicting the likelihood that a patient having dry eye disease (DED) will respond to treatment with an anti-TNFα antibody, or antigen-binding portion thereof, comprising assaying a biological sample from the patient for the presence or absence of a DED response marker, the presence of which indicates an increased likelihood that the patient will respond to treatment with the anti-TNFα antibody, or antigen-binding portion thereof, and wherein the DED response marker is the rs1800693 C / C allele, and the anti-TNFα antibody, or antigen-binding portion thereof, is a) a VH domain comprising the amino acid sequence set forth as SEQ ID NO:8, and a VL domain comprising the amino acid sequence set forth as SEQ ID NO:7; b) a VH domain comprising hypervariable regions as set forth in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and a VL domain comprising hypervariable regions as set forth in SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6; or c) the sequence of SEQ ID NO: 9 A method comprising:
13. 1. A method for generating information in a transferable form for predicting responsiveness of a patient having dry eye disease (DED) to treatment with an anti-TNFα antibody, or antigen-binding portion thereof, comprising: a) determining an increased likelihood that the patient will respond to treatment with the anti-TNFα antibody, or antigen-binding portion thereof, if a DED response marker is present in a biological sample from the patient, wherein the DED response marker is the rs1800693 C / C allele; and b) recording the results of said determining step in a tangible or intangible form for use in communication; Including, the anti-TNFα antibody, or antigen-binding portion thereof, a) a VH domain comprising the amino acid sequence set forth as SEQ ID NO:8, and a VL domain comprising the amino acid sequence set forth as SEQ ID NO:7; b) a VH domain comprising hypervariable regions as set forth in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and a VL domain comprising hypervariable regions as set forth in SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6; or c) the sequence of SEQ ID NO: 9 The method includes:
14. The method of claim 12, wherein the assay comprises assaying the biological sample for a nucleic acid product of the DED response marker, a polypeptide product of the DED response marker, or an equivalent genetic marker of the DED response marker.
15. 15. The method of claim 14, wherein the assay comprises assaying the biological sample for a genomic sequence of the DED response marker.
16. 16. The method of claim 12, 14 or 15, wherein the assay comprises a technique selected from the group consisting of Northern blot analysis, polymerase chain reaction (PCR), reverse transcription polymerase chain reaction (RT-PCR), TaqMan-based assays, direct sequencing, dynamic allele-specific hybridization, high-density oligonucleotide SNP arrays, restriction fragment length polymorphism (RFLP) assays, primer extension assays, oligonucleotide ligase assays, single-stranded conformational polymorphism analysis, temperature gradient gel electrophoresis (TGGE), denaturing high performance liquid chromatography, high-resolution melting analysis, DNA mismatch binding protein assays, SNPLex®, capillary electrophoresis, Southern blots, immunoassays, immunohistochemistry, ELISA, flow cytometry, Western blots, HPLC, and mass spectrometry.
17. 17. The method of any one of claims 12 to 16, wherein the biological sample is selected from the group consisting of synovial fluid, blood, serum, faeces, plasma, urine, tears, saliva, cerebrospinal fluid, a white blood cell sample and a tissue sample.
18. The method of any one of claims 12 to 17, wherein the DED is moderate to severe.
19. The method of any one of claims 12 to 18, wherein the anti-TNFα antibody is a recombinant antibody.
20. 20. The method of claim 19, wherein the anti-TNFα antibody is LME636.
Citation Information
Patent Citations
Stable and soluble antibodies
JP2013544078A
Novel applications for modified human tumor necrosis factor receptor-1 polypeptides
JP2015525237A
Use of TNF receptor antagonists for treating dry eye
WO2009052140A1
